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ABSTRACT
Chagas Disease, also known as American Trypanosomiasis, is endemic to Latin American and is
gradually making its way to other countries. The disease is caused by Trypanosoma cruzi, a
protozoan parasite that causes lesions and inflammation of organs including the heart, esophagus,
and colon. Over 30% of people infected will develop heart disease which can be fatal if untreated.
While no vaccine is yet available, research is currently being conducted in finding new treatments
for the disease. One target is an enzyme that is believed to help the progression of the disease.
Cruzain, a cysteine protease expressed as a pro-enzyme, has been a target since it was discovered
that inhibition of the enzyme reduces proliferation of the parasite. Current research is targeted on
finding small molecule inhibitors that will interact with fully active cruzain. In our study, we
describe a bottom-up approach for the arrest of protein folding.

The role of the pro-domain in

the folding and maturation of the enzyme is studied by comparing oxidative folding of procruzain
and cruzain and by identifying structure stabilizing amino acid residues. The result of these studies
can provide a novel approach to the development of Anti-Chagistic treatments and may even be
useful in combating other protease-dependent diseases.
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CHAPTER 1
INTRODUCTION TO CHAGAS DISEASE AND CRUZAIN
1.1 Chagas Disease
Epidemiology and Incidence
Chagas Disease is endemic to many Central and South American countries affecting
millions of people. The disease is caused by the protozoan flagellate parasite Trypanosoma cruzi
most commonly found in Triatoma insects that cohabitate with the human population in rural,
tropical regions1. It was first described in a small female child by Carlos Chagas, a Brazilian
physician, in 1909 but was not considered endemic until 40 years later.2

Today, more that 11

million people worldwide are infected with T. cruzi and 10-30 percent will develop the disease.
Of the Chagistic patients, 50,000-100,000 will die due to heart failure or swelling of
gastrointestinal and nervous system organs cause by the parasite.1 Over 70 million people are
susceptible to the disease, causing at least 10,000 deaths per year.3
Of great concern is the migration of infected individuals to the United States. These
individuals spread the disease by providing blood for transfusions and organs for transplants which
were not previously screened for T. cruzi. The parasite has also been transferred congenially and
accidentally in laboratory studies. The vector has also been found in non-tropical regions through
migration. In addition to the Unites States; Canada, Europe and Australia are among other regions
where the disease has been detected but to a much lesser extent than in South America.4 Of the
counties outside of the endemic regions, the US is the most widely affected country.5
The disease, vector, and etiological agent are making their way to the US by the migration
of infected Latin American people to states such as Texas, California, and Florida. Table 1
1

provides an estimate of cases of infected individuals by state in 2012 and cases where infected
blood was detected (AABB cases) between 2013 and 2017.3 The AABB, previously known as the
American Association of Blood Banks, is an organization that provides the results of blood
screening. The cases of infected blood are believed to come from individuals that contracted the
parasite in their native countries and later migrated to border states of the US. In 2012, California
was believed to have the highest incidence with over 70,000 estimated cases. Texas, follows with
an estimated 37,000 (Table 1).3

Table 1: Estimated cases of T. cruzi in 2012 and infected blood in 2007-2013

Manne-Goehler, 2016

Though the presence of both the vector and parasite has been declining in Latin America
over the years due to measures taken by the Pan American Health Organization and other entities,
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the incidence in the North America has increased.6 In Texas, before 2005, very few people were
diagnosed with Chagas disease but many people, pets, and animals in the wild were found to be
infected with T. cruzi4 Today, over 200,000 cases of the disease have been detected across the
country.5,3 Though, the number of documented cases has not increased significantly, this data does
not show information provided from undocumented migrants which has recently been estimated
at over 11 million people, 300,000 of whom may be infected. As migration continue to rise, so
will the incidences of disease however due to screening of donated blood, it is believed that fewer
incidences will be found to have been spread domestically.6
Currently, ELISA (enzyme-linked immunosorbent assay) based tests are approved by the
FDA as screening tools for T. cruzi. The ORTHO T. cruzi ELISA Test System, manufactured by
Ortho-Clinical Diagnostics is the current method of detection of the parasite7. Other mechanisms
for detection are currently being developed and some exist to dismiss false results given by the
current method.1 Figure 1 illustrates the cases of Chagas disease reported in Texas by 2005 and
the distribution of individuals and non-human hosts that have tested positive for T. cruzi.

3

Figure 1: Incidents of T. cruzi and/or Chagas Disease in Texas
The infected vector has been found near the southeast and far west regions of Texas. Gray: Triatoma species,
Black: Infected vector or non-human source found, Black with diamond: Humans bitten by Triatomine bugs,
Black with square: Chagas disease detected.4

As shown in Figure 1, cases of Chagas or presence of the Triatomine bugs in Texas is
localized to the southern and southeastern regions of the state, however the Triatomine species
carrying the parasite have also been documented in West Texas and have additionally been found
in New Mexico, Arizona and a high amount of cases have been recorded in New York3. With the
migration of immigrants to the Unites States continuously increasing, the disease is sure to spread
over time if not controlled.
Etiological Agent and Infection
The Triatomine insect is the principal vector of the protozoan parasite. There are over 130
species of Triatomine insects, many of them sylvatic, usually do not infect domestically8 however
4

in endemic countries, the population co-resides with the insect making them susceptible to
exposure. The primary species that carries the parasite, Triatomine infestans9, can be seen in
Figure 2. Several Triatoma species have been found in the Unites States. Figure 3 is a photograph
of 11 species of Triatoma found in the US that have been proven carriers of the parasite.8

Figure 2: Picture of Triatoma infestans
Triatoma infestans is the main vector that carries the parasite that causes Chagas disease.9

Figure 3: Vectors of the parasite T. Cruzi found in the United States.
Most of the vectors found in the US are of the Triatomine species8 photo by S. Kjos.

The infected blood sucking Triatomine insects commonly known as “kissing bugs” contain
the parasite in its mid gut as the epimastigote (insect) form where it can multiply. The parasite
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will then travel to the insect’s hind gut as a trypomastigote. As the insect feeds on its host it
defecates leaving T. cruzi on the skin. A person who has been bitten will scratch the affected area,
causing lesion in the skin allowing the parasite to enter the blood stream in a trypomastigote form10.
Figure 4 is a picture of a Giemsa stained trypomastigote form of T. cruzi, the etiological agent.
The parasite can also enter the body via mucosa membranes of the eyes and other tissues11. After
the human host is inoculated with T. cruzi it will then infect lymphocytes, the white blood cells
responsible for responding to the foreign antigens1.

Figure 4: Picture of the T. cruzi
Blood smear of T. cruzi trypomastigote, a protozoan parasite, is the causative agent of Chagas Disease stained
with Giemsa.12

Macrophages are the primary immune response to defend against the parasite, therefore
along with eosinophils are the most widely infected cells. Within the cells, the trypomastigotes
are transformed to the amastigote form, which proliferate by binary fission. The cells then rupture
and the amastigotes are released into the blood stream to prepare for the next cycle. Other blood-

6

sucking insects become infected as they feed on infected hosts. Eventually, the parasite reaches
the endothelial cells of the cardiac, nervous, and smooth tissues resulting in cardiomyopathy,
megaencephalitis, and megacolon.1 Figure 5 is a H&E stained slide of cardiac tissues infected
with amastigotes of T. cruzi.12 Figure 6 summarizes the life cycle of T. cruzi within the parasite
and the human host.8

Figure 5: Heart muscle tissues infected with T. cruzi
Cardiac muscles tissues were stained with hematoxylin and eosin (H&E). The amastigote form visible in purple
is found in tissues where trypomastigote form are found in the blood.12

7

Figure 6: Life cycle of Trypanosoma cruzi within the vector and host
The life cycle of the parasite in the Triatoma insect (red arrows) and in the human host (blue arrows) are shown.8

The parasite infects and survives within the cells that are responsible for engulfing and
destroying antigens and survives even in the presence of oxidative stress. Trypanosoma cruzi has
evolved to become resistant to reactive oxygen species and mechanisms by which the cells
eliminate foreign substances. Studies show that T. cruzi contains specialized enzymes that allow
the parasite to exist within the harsh environment of macrophages and other white blood cells.1

8

Clinical Manifestations
Chagas Disease is characterized by two phases: An acute and chronic phase. It affects
women and men equally from the ages of 20-50 but can also infect children. The disease in the
acute phase is usually undetected.13 It can be characterized by irritation, swelling at the site of
transmission, nausea, diarrhea, and fever.11 In some cases, swelling of the eyes called Romaña's
sign (Figure 7) is visible near the site of infection.14 The Triatoma species of the insect tend to
bite around the nose and mouth regions which is why it is commonly referred to as the “kissing
bug”. In rare cases the acute phase progresses to heart disease, gastrointestinal and nervous system
failure. The parasitemia is highest in the acute phase and can be detected in the blood. This stage
lasts approximately 6-8 weeks however, patients usually do not experience severe symptoms
therefore do not seek medical attention and screening.11

Figure 7: Romaña's signs of infection
A swollen eye is one of the symptoms of infection.13

9

An intermediate phase follows which can be asymptomatic. This phase can last years and
even decades without ever showing signs of chronic infection. Many people living with Chagas
disease spend their entire lifetime in the intermediate phase. Clinical manifestations of the chronic
phase include cardiomyopathy, megaencephalitis, and megacolon. Heart disease caused by
Chagas is the main cause of death in Latin America. Other symptoms include swelling of heart
valves and gastrointestinal tract.13 Swelling and lesions in the affected organs may be due to
autoimmune response or the persistence of parasites in the circulatory system15 however, since
parasite load at this stage is relatively low, it is more difficult to detect Chagas disease at the
intermediate or chronic phase.13
Current Treatment
The treatment of Chagas disease includes administration of two main drugs: nifurtimox
and benznidazole, Figure 8. The therapeutics treatments are most effective during the acute phase
of the disease however the disease is not usually detected until the chronic stage is reached, a point
at which it is likely organ damage and swelling has already occurred. The effectiveness of the
treatment decreases as time passes. These two drugs are not free of side effects therefore
development of other modes of treatment is essential16. Some of the many side effects include
fever, neurological toxicity, gastrointestinal irritation and allergic reactions17. The first line of
treatment is benznidazole, a nitroimidazole drug, since the side effects are less severe that those
from nifurtimox.18 Other azole-based drugs such as itraconazole have been tested as antiChagistics are based on anti-fungal medication but are not as effective as the current treatment.19,16
The mode of action of these azole anti-parasitic drugs is not fully understood but it is believed that
benznidazole is metabolized by the parasite to produce a reduced hydroxylamine compound. The
reduced compound breaks apart to produce a cytotoxic and mutagenic substance which may attack
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the parasite’s DNA. This drug is also believed to prevent expression of or inhibit enzymes that
are responsible for parasitic survival during oxidative stress. Nitrofurtimox, a derivative of
nitrofurane, is metabolized by parasitic enzymes to produce radicals that also cause oxidative stress
and destabilize the parasitic DNA.19

Figure 8: Current drugs used to treat Chagas disease
Benznidazole (1) is the primary drug used for the treatment of Chagas disease and Nifurtimox (2) is an alternate
treatment.19

Both compounds contain a nitro group at the imidazole ring that is reduced to highly reactive
metabolites. Additional side effects may result from metabolism of the drugs are extensive and can be
found in the Table below.

The side effects are dose dependent and while some are rare, they can be

damaging.
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Table 2: Side effects associated with recommended dosage of anti-Chagistics8

The most common means of prevention is through the administration of insecticides in
endemic regions. This can also be problematic because insecticides can be toxic. Research on
vaccines as a mode of prevention and small molecule inhibitors of the major cysteine protease of
T. cruzi, cruzain, is currently being conducted.20 Administration of a vaccine may cause an over
active immune response, so introduction of the parasite though vaccine can cause the same immune
response leading lesions in organs that result similar to those that T. cruzi produces as it
12

proliferates.1 A major chemotherapeutic target for the treatment of Chagas disease is cruzipain,
the major cysteine protease localized in lysosomes of T. cruzi. This enzyme was named for its
homology to papain and after Oswald Cruz, mentor of Carlos Chagas. It belongs to the
papain superfamily of proteins and is homologous to papain and the cathepsins. The name
cruzipain is given to the full enzyme within the parasite and the recombinant form without a Cterminal domain extension is known as cruzain. Cruzipain is present in all stages of the protozoan
life cycle21 which makes it an attractive target. The proteolytic enzyme takes part in the infection
process, provides nutrition to the parasite and combats the immune response. Papain-like proteases
are known to hydrolyze regions of immunoglobulin G (IgG) antibodies that present antigens to
phagocytes for degradation. In epimastigotes, cruzipain is a 60kDa protein composed of two
domains, one mostly comprised of alpha helices and another of beta sheets.22 Current research is
being conducted to produce inhibitors of cruzipain.

1.2 Cruzain as a Target
Proteases
Proteases are enzymatic proteins that catalyze the hydrolysis of proteins. Also known as
peptidases or proteinases, these enzymes break the amide bond between amino acids in a
polypeptide chain. They may break bonds at certain residues producing fragments or may be nonspecific and degrade at all peptide bonds to produce individual amino acid residues.23 Proteases
are present in all organisms and contribute to a variety of processes including but not limited to
cell death, growth, repair and digestions depending on location and type. Proteases are of the
mostly widely studied enzymes and are highly produced using recombinant techniques. It is
estimated that proteinases make up about 60% of enzymes expressed organisms.24 Proteases are
normally synthesized as inactive zymogens for regulation and often undergo autoactivation by

13

removing the prodomain that inhibits catalysis. The prodomains are believed to behave as
chaperone-like region of proteases which may allow the protein to achieve the native structure.
These regions of proteases involved in disease are currently being studied as a target of inhibition.
Hydrolysis of proteins is important for the degradation of aged cellular material and
production on newly synthesized peptides. Peptidases can be classified in several ways depending
on the identity of the catalytic moiety, the chemical mechanism of degradation and homology with
other proteins. There are two main types of proteinase: endopeptidases and exopeptidases.
Endopeptidases catalyze the hydrolysis of a peptide bond within the substrate peptide strand at
certain amino acid residues.

Exopeptidases cut peptide bonds at the amino terminus

(aminopeptidases) or carboxyl terminal (carboxypeptidases) of a target protein23. It is estimated
that approximately 2% of expressed proteins are proteases.24
These enzymes can be isolated from plants, animals, microbes and are often mass produced
by recombinant DNA technology.

Most of proteinases initially come from animal sources but

considering regulations and concerns with animals as a source, many advances in recombinant
DNA technology have been improved over time to produce higher yields of proteins. Figure 9
provides a comparison between extraction of proteinases from living organisms versus those
produced by biotechnological advances.

14

Figure 9: Production of Proteolytic Enzymes
Comparison between production of proteinases from living organisms and through recombinant technology.24

Both methods will involve processing of cells containing the enzymes of interest, as well
as purification of and characterization of the enzyme. One advantage of extracting proteinases
directly from the source is that after separation of the gene products, the exact genetic makeup of
proteins can be determined. To express proteins via DNA recombinant technology, the amino acid
sequence must be known which should be determined directly from the source.

After

determination of the amino acid sequence plasmids can be produced and inserted into vectors that

15

will produce proteins in mass quantities, often as inclusion bodies. This method is commonly
used in industry.24 Proteases are widely studied however they are costly.
Proteinases can be subclassified according to catalytic amino acids with in the active site. The
subclasses of proteases include: threonine, aspartate, glutamic acid, serine proteases, cysteine and
metalloproteases. Many of the subclass of proteases have highly conserved catalytic dyads and
often triads that carry out the enzyme activity.
Threonine proteases contain a threonine residue in their catalytic domain. The secondary
alcohol of the residue behaves as a nucleophile to form an intermediate that is subsequently
hydrolyzed. Threonine proteases are a major component of proteasomes, large complexes that
degrade aged or damaged proteins. Aspartate proteases contain an aspartic acid residue in the
catalytic region. These proteases produce an activated water molecule that can attack the substrate
during hydrolysis. Examples of aspartic acid proteinases include pepsin and cathepsin D. They
are also involved in digestion and blood pressure control. Glutamic acid proteases contain a
glutamic acid residue in the catalytic core.24 Metalloprotease contain a divalent metal ion25 such
as Zn2+. One example is thermolysin, a metalloproteinase commonly found in Bacillus species.
Metalloproteinases that are found in the tissues of vertebrates include collagenases, others are
involved in would healing and tumor metastasis.
There are 20 families of the serine proteases, all which have a highly conserved catalytic
triad containing aspartate, histidine and serine residues. Similar to threonine proteinases, serine
proteinases have nucleophilic alcohol in the active site.26 One example of serine protease is
subtilisin, a bacterial serine protease first isolated from Bacillus subtilis. The role of the prodomain
of these proteases is widely studied. Chymotrypsin and trypsin are additional examples of serine
peptidases. Chymotrypsin hydrolyzes at phenylalanine, tyrosine and tryptophan while trypsin
16

cleaves at the C-terminal of arginine and lysine residues. These enzymes create fragments of
protein that can be separated by liquid chromatography and studied by mass spectroscopy. Serine
proteases are often found in the animal pancreas, assist in digestion, blood clotting and immunity.27
Cysteine proteases, also known as thiol proteinases, contain a cystine residue in the catalytic
core. Many contain a highly conserved catalytic triad that includes cysteine, histidine and
asparagine. These proteases have been widely studied as a target for a variety of diseases28. Some
examples include papain, calpain and cathepsins B, H, L. These enzymes are divided into four
subtypes: papain-like, glutamic acid-like, trypsin-like and others that do not fit any of those
classifications24. Papain, isolated from the papaya fruit, was the first cysteine proteinase to be
isolated and characterized.29 Calpain are cysteine proteases that contain a calcium ion in the
catalytic domain24. Human cathepsins are part of the papain-like family of cysteine proteases and
can be found in epithelial cells, thymus and testis. Some cathepsins play a significant role in
immunity and are expressed on antigen presenting cell, T-cells and natural killer cells while others
are involved in bone resorption.30 The cathepsins and other cysteine proteases are a target of study
for their involvement in cancers, arthritis and immune system related disorders. Parasitic and viral
cysteine proteases are among the most widely studied for their role in diseases such as Chagas
disease, African sleeping sickness, AIDS, and malaria.29 Parasitic cysteine proteases are important
to the survival and proliferation of the parasite and are present in all stages of the parasitic life
cycle which make parasitic cysteine proteinases an important therapeutic target.
Cysteine Protease Structure, Activation, and Proteolytic Mechanism
Cysteine proteases are often found within lysosomes, the degradation compartment of the cell.
Lysosomal cysteine proteases are active under acidic conditions and tend to lose their activity at
physiological pH therefore it is not common to find an active cysteine protease outside of the
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lysosome.

In fact, in neutral conditions, these enzymes tend to denature and aggregate.

Structurally, they contain a prodomain, catalytic domain, c-terminal extension and signal
sequence. Similar to other proteases, cysteine proteases are synthesized a precursor protein. The
prodomain of these zymogenes covers the catalytic domain to prevent auto-degradation and can
range from 30 to over 200 amino acids in length. The sequences and structures of papain-like
cathepsins are widely characterized. Figure 10 is an illustration of different types of cathepsins
in which the prodomains range in size. There are over 10 members of human cathepsins and many
of the structures have been characterized by x-ray crystallography. Other cysteine proteases have
been studied using techniques applied to isolate and characterize the cathepsins.30

Figure 10: Comparison of the pro- and catalytic domains of different cystine proteases
Green regions denote prodomains while the purple regions designate the catalytic domains. Of the examples
listed, most are Cathepsins.29
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Cysteine proteases can mature by both auto-activation and trans-activation31. The pro-domain
of many papain-like proteases such as the cathepsins interacts with the catalytic domain through
salt bridges, hydrogen bonding and hydrophobic interactions. Based on previous studies on
cathepsin L, it is believed that many papain-like proteases undergo activation in acidic or reducing
conditions causing a disruption in the salt bridges formed between charged residues in the
prodoamin which in turn causes a disruption of hydrogen bonding and hydrophobic interactions.
The interruption of the interactions within the prodomain cause structural changes in the protein
which no longer allows the prodomain to block the catalytic core. Exposing the catalytic core may
then allow for autoactivation. Once activated, mature enzyme can further activate the zymogens
in a trans-activation mechanism thus, activation can be unimolecular and bimolecular.32
Once mature, the active site is free to catalyze protein degradation. Cysteine proteases break
peptide bonds by nucleophilic attack of the cysteine thiol. The sulfur of cysteine is not very
nucleophilic however the histidine in the catalytic triad increases the nucleophilicity of the thiol
by the interaction of the imidazole ring with the hydrogen of the cysteine sulfhydryl resulting in a
thiolate-imidazolium dyad. The thiolate- imidazolium interaction may be stabilized by the
asparagine of the catalytic triad. The thiolate being a stronger nucleophile than the sulfhydryl
attacks the carbonyl carbon of the scissile bond within the substrate protein displacing the pi
elections of the carbonyl, creating tetrahedral intermediate oxyanion hole. As the double bond of
the carbonyl regenerates the nitrogen of the scissile bond leaves. Water attacks the carbonyl, once
again displacing the pi elections, producing a tetrahedral oxyanion hole. As the double bond
regenerates, the thiolate is cleaved. Glutamate may help generate and stabilize the oxyanion
holes.33 Figure 11 summarizes the catalytic mechanism of cysteine proteases. Cysteine proteases
often cleave at phenylalanine and arginine residues.
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Figure 11: Cysteine protease mechanism.

Red arrows the transfer of electrons from nucleophile to electrophile. The green box highlights the
substrate protein.34

Parasitic cysteine proteases are currently a target for the prevention and treatment of
diseases. Parasites that cause neglected tropical diseases (NTDs) affect over a billion people
worldwide. Latin America, Africa and Asia are among the regions most affected35. Chagas
disease, a NTD caused by Trypanosoma cruzi, is the main cause of heart disease in Latin America.
Human African trypanosomiasis is an NTD cause by Trypanosoma brucei that eventually leads to
neurological disorders.36 Over 10,000 cases of infection are documented each year, leaving over
70 million susceptible to the disease37. Cysteine proteases are present in every stage of the parasitic
life cycle and are involved in invasion, nutrition, reproduction and progression of disease 33
therefore are considered a valuable target for prevention and treatment of diseases caused by the
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parasites. Current drug discovery efforts involve the development of small molecule inhibitors
that arrest progression of disease by preventing cysteine protease catalytic activity.38 Though many
small molecules have been developed over the years, none have reached as far as human clinical
trials.
1.2.3 Structure and Function of Cruzipain
Cruzipain is a cathepsin-like cysteine protease of the papain family found in T. cruzi.
Because if its presence in all stages of the parasitic life cycle, it is a major therapeutic target. The
DNA sequence was deduced by Eakin et.al. in 1992 and the crystal structure of the mature
proteinase was produced shortly after. The endogenous enzyme was expressed within each form
of the parasite but the expression of cruzipain, the full prepropeptide, was highest in the amastigote
form. A 1.85 kbp DNA sequence from T. cruzi was isolated, sequenced and compared to other
cysteine proteases for classification. The full sequence of prepropeptide was found to be most
homologous to the cysteine proteases found in T. brucei and a murine cathepsin-like protease both
belonging to the papain family; hence the full protein was named cruzipain. It was found that 6
copies of the gene are located within the parasite’s genome, giving an insight to its significance.
Figure 12 provides the organization of the vector that was constructed to contain the cruzipain
domains, which was expressed in bacteria and purified for analysis of enzymatic function. The
major domains include the CheY signal sequence, prodomain, protease core and a c-terminal
extension.39
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Figure 12: Genetic organization of cruzipain
The regions of the genome that are highlighted include the pro-domain, protease core and the c-terminal
extension.39

The truncated version of cruzipain, cruzain, is commonly used for anti-Chagistic studies.
The proenzyme is expressed as a 215 amino acid residue-long protein lacking the c-terminal
extension, which undergoes autocatalytic activation to produce the mature enzyme. Over 25
crystal structures of cruzain inhibited with a small molecule are available in the Protein Data Bank,
however no crystal structure of procruzain exists to date.40 Figure 13 is an x-ray crystal structure
of the active enzyme containing a small molecule inhibitor in the catalytic domain. The structure
of mature cruzain is composed of two main types of domains, an alpha helical domain and a beta
pleated domain. The active site located between the major domains.41,42 Also highlighted is the
catalytic triad, a highly conserved region among cysteine proteases, in which cysteine and histidine
are essential to the function. Figure 13 is a structure generated by PyMol of the catalytic triad
consisting of Cys25, His159, Asn175, common in papain family members.42 The enzyme also
contains three disulfide bonds that can be of great importance when studying the folding
mechanism of the protein as it is being synthesized with in the cells.
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Figure 13: X-ray crystal structure of cruzain
Cruzain crystallized with a small molecule inhibitor in the active site.41

Figure 14: Cruzain catalytic triad
The cruzain catalytic triad consists of Cys25, Hist159, and Asn175 (pink). Glutamin19 and Tryptophan177 are
essential for the efficient protease activity but not part of the catalytic triad. Green arrow indicates active site.42
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It has been found that cruzain is not only located in lysosomes but also on the surface of
the cell and the flagellar region.44 Cruain is believed to play a significant role in invasion of cells,
differentiation of the parasite, and blood break down for nutrition.45 High titers of IgG were found
in the blood of infected individuals however, cruzain uses its proteolytic activity to escape the
immune system.46 Studies have proven that cruzain degrades immunoglobulins leaving free Fab
segments that can localize around the parasitic surface, allowing them to escape phagocytes.47
Figure 15 highlights the hinge region of IgG, the location of degradation of Fab from Fc regions
of the antibody. Another mechanism for evasion of the immunes system is cleave of transcription
factors by cruzain causing a deactivation of macrophages.

Figure 15: Structure of IgG
Cruzain cleaves at the hinge region of IgG (highlighted in pink), releasing Fab domains (structure of IgG
from45 which then are available to coat the parasite and avert the immune response47.

The C-terminal extension is not believed to be involved the protein’s catalytic activity
therefore “cruzain” is suitable for studies. In our investigation, procruzain is expressed as a 35kDa
inactive zymogen that must be activated to the 26kDa mature enzyme.48,49 Currently, small
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molecule inhibitors of this protease are being synthesized and analyzed for treatment as a point of
inhibition of the enzyme however, problems exist with irreversibility, bioavailability and tolerance
of the novel chemotherapeutics. Aside from these challenges, cruzain is homologous to human
proteins like Cathepsin L which can create side effects. Recent studies on numersou inhibitors
claim that the specificity is high enough to not interfere with human gene products and do not
create side effects, but further studies must be conducted to determine long term effects.50
1.2.4 Implications in Treatment and Prevention of Chagas Disease
Due of the lack of efficiency of current treatment of Chagas disease, cruzain is a highly
studied target for the development of novel therapeutics. Benznidazol and nifurtimox are only
effective in treatment during the early onset of the disease (the acute stage) however, most cases
go undiagnosed until the chronic stage is reached and the illness become more debilitating.
Nifurtimox (a nitrofuran) and benznidazole (a nitroimidazole) and were discover in 1965 and 1971
respectively and later approved for the treatment of fungal infections. Other antifungals were
tested against T. cruzi but were proven ineffective. Recently, fexinidazole, a nitroimidazole similar
in structure to benznidazole has been tested for the treatment of Chagas disease in both the acute
and chronic phases. It was shown to cure over 90 percent of acute and chronically affected mice
however the sample in the study was small (n=6). Surprisingly, fexinidazole (Figure 16) was more
effective at treating infected mice in the chronic stage than the acute stage. This may be because
the parasite is restricted to fewer locations within the body and not widely systemic like in the
acute phase.51 In 2014, fexinidazole was under Phase II of clinical trials. In Bolivia, the drug was
administered to 47 patients but the study was interrupted due to safety issues and drug
intolerability. In 2018, the drug re-entered Phase II in Spain and with significant efficacy will
continue to 2019 and conclude in 2020.52
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Figure 16: Structure of fexinidazole
The structure shows that this molecule is a nitroimidazole derivative. It is currently being investigated as
treatment for Chagas disease and other parasitic infections.52

As previously mentioned, current research is being conducted on inhibiting the active site
of cruzain with small molecules. High-throughput screening methods have identified several
classes of inhibitors, many of which have been synthesized and tested against cruzain. Upon
finding effective inhibitors, pharmokinetics are constantly being improved. While effective in
interacting with the active site of cruzain, issues with the bioavailability and half-life of the
molecules still remain.38 Fluoromethyl ketones were among the first inhibitors synthesized to
block activity of cruzain.53 Vinyl sulfonic molecules were also developed against cruzain, the
most effective being K777 (Figure 17). This vinyl sulfone derivative irreversibly inhibits cruzain
in the nanomolar range arresting proliferation of the parasite however the drug is intolerable and
the study ended in the preclinical trials.45 Tetrafluorophenoxy methyl ketones have also shown
efficacy in inhibition at low concentration (IC50 = 3nM) and peptidyl nitroalkanes inhibit cruzain
(IC50 = 0.44nM). An example of a Tetrafluorophenoxy methyl ketones is seen in Figure 18 and
peptidyl nitroalkanes in Figure 20.
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Figure 17: Structure of K777
A vinyl sulfone derivative studied for the inhibition of cruzain.45

Figure 18: Example of a tetrafluorophenoxymethyl ketone

Figure 19: Example of a peptidyl nitroalkene

The following table is a list of additional inhibitors that have been studied for their activity against
mature cruzain but have not yet enter clinical trials.
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Table 3: Additional cruzain inhibitors previously and currently studied

Inhibitor type

Structure

Thiosemicarbazones

Thiazoles

Thiazolidines

Nitriles

Benzimidazole derivatives

Structure found in Ferriera38

Our aim is to avoid small molecule interaction with host proteins by preventing cruzain
from reaching its native state. We call this a bottom up approach because the protein will be
arrested early in its expression, minimizing the proliferation of the parasite and the damage to the
host. Folding rate comparison between cruzain and procruzain and identification of structure
stabilizing residues can lead us to produce small molecules that may prevent three-dimensional
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folding of procruzain. These finding will provide a different angle and novel approach to creating
treatment for Chagas disease.

1.3 Protein Synthesis
Proteins are biological macromolecules composed of amino acids and are responsible for
carrying out many of the cell’s functions within an organism. Proteins are the gene products
encoded by DNA. Each protein has a specific function that is determined by its primary amino
acid sequence.

Some biological processes proteins take part in include catalysis of

thermodynamically unfavorable biochemical reactions, signaling and trafficking of substrates,
defense against pathogens and folding of other proteins.

Protein synthesis involves the

transcription of a single stranded DNA template into messenger RNA followed by the translation
of mRNA to a primary amino acid sequence. Translation is the last step of gene expression but
can be considered the first step in the formation of a fully functional protein. Synthesis of peptide
chains determined by mRNA occurs within free ribosome or those located outside of the
endoplasmic reticulum (ER). 54
There are four levels of organization of a protein that will determine its structure and
function. The primary structure of a protein is the linear sequence of amino acids54. The first full
length amino acid sequence of a protein was determined by Frederick Sanger in 1953. Sanger
discovered the primary structure of insulin, but more importantly revealed that each protein
consists of a specific amino acid sequence that determines the function. The secondary structure
of a protein is the regular arrangements of amino acids within localized regions of the polypeptide
chain.

Alpha helices and beta sheets are formed and stabilized by hydrogen bonds and

hydrophobic interactions. The tertiary structure of a protein is achieved by the interactions
between the side chains of amino acids that lay in different regions of one single peptide chain.
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Hydrophobic amino acids will aggregate to the interior of the protein while hydrophilic amino
acids will be exposed to the aqueous environment surrounding the protein. Also contributing to
tertiary structure is the formation of disulfide bonds between thiol-containing amino acid residues.
Finally, the fourth level of protein organization is the quaternary structure in which two or more
peptide chains come together as subunits to form one functional protein54. Not all proteins reach
a quaternary structure. Figure 20 summarizes the different steps in protein synthesis and the
formation of a functional protein.
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DNA is transcribed to RNA

RNA is translated to an amino acid sequence

Primary amino acid sequences fold to secondary, tertiary, and quaternary structures (beta
sheets and alpha helices shown)

Post translational modification and formation of a functional protein

Figure 20: Summary of protein synthesis.

Transcription, translation, and three-dimensional organization of a protein

Nobel Prize recipient Christian B. Anfinsen, known for the “Anfinsen Dogma” also known
as the “thermodynamic theory”, demonstrated that denatured proteins can spontaneously fold back
to their native three-dimensional conformation and regain activity. This indicates that the native
structure of the protein is determined by the information given in the primary amino acid
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sequence56. Under physiological conditions, the primary amino acid sequence will give rise to the
most thermodynamically stable conformation.57 Catalysts and chaperones facilitate the protein in
achieving a native structure, but it is the protein’s amino acid sequence that determines
conformation56.
During and after synthesis, proteins undergo modification before becoming fully
functional. Secreted, plasma membrane, and lysosomal proteins contain a signal sequence which
allow them to translocate into the ER for post-translational modifications such as disulfide bond
formation and to their final destination. Disulfide bond formation occurs when sulfur from a
cysteine is oxidized and forms a covalent bond with the sulfur from another thiol-containing
moiety. The ER is an oxidizing environment relative to the cytosol allowing disulfide bond
formation to occur.57 Aside from disulfide bonding, other functions of the ER include further
protein folding, multi-subunit formation, initiation of glycosylation, and addition of glycolipid
anchors. ER proteins such as protein disulfide isomerase (PDI) will catalyze the assembly and
formation of secreted proteins by stabilizing unfolded proteins and isomerizing the correct
disulfide bridge formations.58 When the native three-dimensional structure is achieved, the protein
is ready for transport to its intended location. Secretory proteins are transported from the ER to
the Golgi and finally secreted out of the cell.59 Proteins that are to reside in the ER are retained or
transported back to the ER via the KDEL signal sequence.60 Enzymatic activity and protein
function in general, is dependent upon pH. Cytosolic proteins will function at physiological pH,
those in the rough ER are in a slightly basic environment and proteins found in degradation
organelles like the lysosomes will function under acidic conditions. Figure 21 illustrates the
organization of the cell and pathway secreted proteins undergo.
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Figure 21: Organization of the cell
Secretory proteins are synthesized on ribosomes, translocated into the ER, sent to the Golgi and secreted59.

Correct disulfide bond formation is significant to the structure and function of a protein.
Without proper disulfide bond formation, the peptide is degraded or can form aggregates that will
disrupt the overall function of the cell. When unfolded proteins cannot quickly find their
conformation, hydrophobic regions of individual peptides cause insoluble aggregates to form. Not
only can aggregation lead to a loss of protein function but the accumulation can lead to cell death.
Endoplasmic reticulum associated degradation (ERAD), a process where misfolded proteins are
labeled and sent to proteasomes for degradation, helps alleviate protein aggregation.

If

accumulation of misfolded proteins occurs and the cell machinery cannot handle the load, the cell
will experience stress and may become apoptotic.61
Cruzain is considered the main target for the development of anti-Chagastic drugs. The
mature enzyme and the prodomain have been well investigated as separate peptides while the full
length procruzain has been understudied. The purpose of this project is to determine the
involvement and significance of the pro-domain in protein folding of cruzian to impede folding
and arrest the progression of Chagas Disease.
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CHAPTER 2
REFINEMENT OF EXPRESSION, PURIFICATION AND ACTIVATION
OF PROCRUZAIN
2.1

Specific Aim
Specific aim one: To refine the expression, purification and activation method of cuzain.

2.2

Background
Previously, a low yield of mature cruzain was obtained with protocols provided in the

literature therefore our goal was to refine our method to produce a higher yield of active cruzain
for kinetic studies. Production of procruzain and activation methods were adapted from Eakin
et.al.21. Refinement was made in the solubilization of the protein, purification methods and to the
activating conditions. The enzyme, when activated, is extremely catalytic and is subject to
autodegradation, therefore storing conditions were also refined to prevent degradation or
inactivation before experiments were conducted. The expression, purification and activation to
obtain our protein of interest is described here.

2.3

Materials and methods: Expression, purification and activation

2.3.1 Transformation of E. coli DH5 α for Subcloning Efficiency
The plasmid (pQE-30) containing the gene that codes for procruzain with a polyhistidine
tag at the N-terminus kindly provided by Dr. Ana Paula Lima from Federal University of Rio de
Janeiro, Brazil; Biophysics Institute Carlos Chagas Filho was inserted into competent E. coli DH5α
for subcloning efficiency and DNA purification. Figure 22 shows the pQE-30 plasmid map
highlighting the location of the insert containing a PT5 promotor region, lac operon, multiple
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cloning sites, histidine tag (6x), and restriction sites62. The ampicillin resistant gene (ampr) and
origin of replication are also shown. The ampr gene codes for beta-lactamase, an enzyme that
hydrolyzes the beta-lactam ring of ampicillin inactivating the antibiotic. The lac-operon regulates
gene expressionn62.
To produce a DNA stock solution for multiple expression trials, 2 uL of the plasmid with
the procruzain gene inserted at the MCS provided by A.P. Lima was added to 50 uL of DH5α cells
(Invitrogen) and incubated on ice for 30 minutes to allow for mixing. The mixture was heated at
42°C for 50 seconds and placed back on ice for a minimum of two minutes for a heat shock
treatment. The transformed cells were added to 200 uL of SOC media, a variant of super optimal
broth (SOC) media and incubated under slight agitation for 2 hours at 37°C to allow for recovery.
100 uL of the incubated cells were spread on a lysogeny broth (LB) nutrient agar plate containing
100 uM ampicillin (amp) and 50uM kanamycin (kan) final concentration. The plate was incubated
for 14 hours at 37°C then sealed and stored at 4°C to prevent overgrowth and contamination.
The plasmid was extracted and purified from the transformed DH5α cells using the
QIAprep Spin Miniprep kit (QIAGEN)64. To begin plasmid purification, 5 mL of SOC media
containing 100uM amp and 50 uM kan was inoculated with one colony from the previously
transformed DH5α cells and was incubated under agitation at 37°C for 14 hours. The cells were
harvested by centrifugation at 3500 rpm for 7 minutes with an Eppendorf 5804R Benchtop
Refrigerated Centrifuge. The supernatant was discarded and the QIAGEN protocol for plasmid
purification was followed. The harvested pellet was solubilized with a buffer and lysed and the
cellular debris was removed by spinning the cells at 13,000 rpm for 7 minutes with an Eppendorf
5415R Refrigerated Benchtop Centrifuge. The supernatant was applied to the QIAGEN spin
column and eluted with 50 uL of 0.2 um filtered/UV treated Millipore water. The protocol
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produced between 10 and 20 ug of DNA. The purified DNA concentration was quantified with a
NanoDrop instrument and was either directly stored at -20℃ or lyophilized until needed for
transformation of bacterial cells and protein expression.

Figure 22: pQE-30 Plasmid Map
Plasmid, pQE-30 (QIAGEN), contained the gene that codes for pczp at the multiple cloning site (MCS)

Chemically competent cells were prepared by growing a 5mL overnight culture of E. coli
M15 and BL21 expression cells and DH5α subcloning efficiency cells (Invitrogen). The culture
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was diluted the following day in 100 mL LB after growing overnight for no more than 16 hours at
37°C under slight agitation. The inoculated 100 mL culture was incubated at 37°C while shaking
until the optical density (OD) reached 0.40. The absorbance was measured at 600 nm with a
Thermo GENESYS™ 10UV UV-Vis spectrophotometer. After reaching the optimal OD the cells
were harvested at 4°C by centrifugation at 3,700 rpm for 7 minutes. The pellet was resuspended
with 10 mL of 0.10 M calcium chloride/1.0 M pipes buffer at pH 7.4 and incubated on ice for 30
minutes. The cells were harvested and the supernatant was discarded. This step was repeated for
two more cycles and finally the cells were resuspended in 2.0 mL of CaCl2/pipes buffer, incubated
overnight at 4°C, then stored as 50 uL aliquots 1 mL sterile microcentrifuge tubes. Two 50 uL
aliquots of cells were immediately used for transformation and the rest were stored at -80°C for
up to 6 months. This protocol was used to prepare chemically competent DH5α, BL21 and M15
strains of E. coli cells.
2.3.2 Transformation of E. coli BL21 and M15 Cells for Expression of Procruzain
E. coli BL21 is commonly used for overexpression of proteins and M15 contain the genetic
conditions that allow for expression of proteins found on pQE30 plasmids therefore these strains
were each transformed to compare expression levels. 4uL of plasmid obtained from the miniprep
extraction was added to 100uL of BL21 or M15 chemically competent cells prepared as in section
2.31. of this manuscript and incubated on ice for 30 minutes to allow for mixing. Heat shock as
conducted by heating the mixture at 42°C for 1 minute then placed on ice for a minimum of two
minutes. The transformed cells were added to 200 uL of SOC media, a variant of super optimal
broth (SOB) media, and incubated under slight agitation for 2 hours at 37°C to allow for recovery.
100 uL of the incubated cells were spread on a lysogeny broth (LB) nutrient agar plate containing
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100 uM ampicillin (amp) and 50 uM kanamycin (kan) final concentration. The plate was incubated
for 14 hours at 37°C then sealed and stored at 4°C to prevent overgrowth and contamination.
2.3.3 Expression of Procruzian
A small-scale culture was grown by inoculating 100 mL of LB broth containing 100 uM
amp and 50 uM kan with a small colony of transformed BL21 or M15 cells. The culture was
grown overnight at 37°C while shaking. The small-scale culture was diluted 10 times into 1 L of
LB broth containing the same final concentration of antibiotics. The large-scale culture was grown
at 37°C and carefully monitored by checking the optical density at 600 nm periodically. Once the
optical density of the culture reached 0.5 (approximately 2 hours after dilution), 250 uL of bacteria
was removed from the culture and stored as a glycerol stock to reduce the need for additional
transformations. A glycerol stock of transformed cells, either BL21 or M15, was prepared by
adding 250 uL of the bacterial culture to 250 uL of a 60% glycerol stock for long-term storage at
-80℃ in a 1.8 mL capacity cryogenic tube (Nunc® cryotube, Sigma-Aldrich). The glycerol stock
was prepared by adding 125 uL of 100% heat sterilized glycerol to 250 uL of 0.2 um filtered water.
The glycerol stocks were stored at -80℃ for future expressions. Glycerol stock preparation
ensured the viability of transformed cells during long-term storage while reducing the need for
transformations.
After the 1 L culture reached the optimal OD and the aliquot for the glycerol stock was
removed

and

stored,

expression

was

induced

by

adding

1M

isopropyl-B-D-1-

thiogalactopyranoside (IPTG) (1 mM final concentration) and was incubated for 4 hours at 37°C.
The cells were harvested by centrifugation on a Sorvall Model RC-5C Refrigerated Superspeed
Centrifuge and a GSA rotor at 5000 rpm for 15 minutes and the supernatant removed and
discarded. At this point the cells were either lysed or stored at -80°C for a maximum of 6 months.
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Expression of a mutant of cruzain was done in a similar manner to the expression of
procruain. The gene that codes for the mutant lacking the cysteine of the catalytic triad was
inserted into pQE-30 with a histidine tag at the N-terminal domain. E. coli (DH5α, M15 and BL21)
cells were transformed to produce the mutant. Purification, refolding and storage was done using
the protocol below. The C25A mutant was expressed to determine the role of the pro-domain in
activation and folding.
2.3.4 Cell Lysis and Purification
The chaotropic agent urea at high concentration (8M) in a lysis buffer (10 mM Tris, 100
mM NaH2PO4 pH 8.0) was used to lyse the cells and disrupt the expressed procruzain inclusion
bodies. For a 1L culture, 100 mL of lysis buffer (1/10 total volume of inoculated media) was
applied to the pellet. The cells were lysed at 4°C under slight agitation for 1 hour. To increase
solubilization of the proenzyme and maximize lysis, the cell lysate was sonicated with 40 W output
Branson Ultrasonics Sonifier 450 for 3 x 30 second pulses while on ice. The lysate was allowed
to recover for 1 minute in between 30 second pulses.

A final concentration of 1 uM

phenylmethylsulfonyl fluoride (PMSF) was added to prevent degradation of the protein by serine
proteases. Active cruzain is a cysteine protease therefore protein cocktail inhibitors (PIC) and
cysteine protease inhibitors such as trans-epoxysuccinyl-L-leucylamido-(4-guanidino) butane (E64) and leupeptin were avoided during lysis when activation was desired otherwise were added to
a 1 uM final concentration. The cellular debris was removed by centrifugation at 11,500 rmp for
20 minutes using a Sorvall Model RC-5C Refrigerated Superspeed Centrifuge with a SS-34
Superspeed centrifuge rotor. The supernatant containing procruzain was applied to glass EconoColumn® Chromatography low pressure/gravity flow column containing 3mL divalent nickel
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coordinated nitrilotriacetic acid agarose resin (Ni-NTA His•Bind®, EMB Biosciences) preequilibrated with lysis buffer for purification.
The Ni-NTA metal chelating resin stored in 20% ethanol was rinsed with water and
equilibrated with lysis buffer containing 10mM imidazole. The mixture was incubated with the
supernatant at room temperature under slow agitation for 20 minutes to allow for binding then
added to the gravity column. The flow through was released, collected and stored at 4°C. The
beads were washed with 5 mL of wash buffer (10mM Tris, 100 mM NaH2PO4, and 8 M urea pH
6.3) for a total of 5 washes. The protein was eluted in 2 mL aliquots with elution buffer (10 mM
Tris, 100 mM NaHPO4, 8.0 M urea, 200 mM Imidazole at pH 8.0) for a total of 15 fractions. The
nickel resin was be cleaned by incubating the beads with 5 mL of 0.1M acetic acid-acetate buffer
at pH 4.0 for 5 minutes then re-equilibrated with excess lysis buffer.
regenerated as directed by the supplier.

After 5 uses, the resin was

Sodium dodecyl sulfate polyacrylamide gel

electrophoresis (SDS-PAGE) described below was used to examine purification. Pure fractions
were collected and stored at -20℃ until protein folding studies were conducted.
Aliquots (25 uL) of each stage of the purification process were analyzed by SDS-PAGE.
The samples were mixed with and equal volume of 2x sample buffer under reducing and
denaturing conditions (4% SDS, 20% glycerol, 10% 2-mercaptoethanol, 0.004% bromophenol
blue and 0.125 M Tris HCl, pH 6.8) and incubated at 90℃ for 2 minutes. The samples were
allowed to cool and 15 ul of each were loaded on a hand casted 12% polyacrylamide gel (37.5:1)
along with 5 uL of Precision Plus protein standard (BioRad) then applied to a BioRad Mini-Protean
II vertical electrophoresis system. Migration of protein samples was achieved by applying 100 V
of current until the dye front of the sample buffer reached 1cm from the bottom of the gel. The
current was provided by a BioRad PowerPac Basic Power Supply. The gels were stained with
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Coomassie dye (Sigma-Aldrich) containing 1 g of Coomassie Brilliant Blue R250, 100 mL of
glacial acetic acid, 400 mL methanol and 400 mL of Millipore treated water and placed on a
platform rocker for 20 minutes. The gels were rinsed with doubly distilled (ddH2O), resolved with
destaining solution (staining solution lacking Coomassie powder) and viewed on a UVP LMW20
UV/White Light Transilluminator.

Images were taken with a UVP BIODOC-IT UV

Transilluminator Imaging System.
2.3.5 Refolding of Procruzain
The pure aliquots shown by SDS-PAGE were pooled together and the concentration was
determined with the BioRad DC Protein Assay Kit.

This assay for protein concentration

determination was used in place of Bradford assay or Lowry method because it is compatible with
a high concentration of urea (4 M urea and above). 10-15 mM dithiothreitol (DTTred) per milligram
of purified protein was added to the pooled fractions and incubated at 37℃ under slight agitation
for 1 hour to fully reduce disulfide bonds.
Procruzain was refolded by diluting the reduced and denatured protein 100 times in
refolding buffer (250 mM arginine, 100 mM Tris HCl, 1 mM ethylenediaminetetraacetic acid and
20% Glycerol, pH 8.0) and incubated under slight agitation at 4˚C overnight. The solutes were
partially removed by displacing the refolding buffer with 1L of phosphate buffer using an Amicon
Dialfiltration unit. The sample was concentrated to 20 mL, the concentration determined with the
Bradford assay and prepared for activation. Dialysis was avoided due to precipitation of the
enzyme.
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2.3.6 Activation and Purification of Mature Enzyme
Precipitates that may have formed within the purified product were removed with a 13 mm,
polyvinylidene fluoride, 0.22 um pore size syringe filter (Whatman). Initial activity of the of the
purified protein was analyzed by fluorescence spectroscopy on DM45 Spectrofluorimeter (On-line
Instrument Systems, Inc.) using Spectra Works software in a quartz cuvette (Fisher Scientific) with
a 1cm path length containing four transparent walls. Fluorescence was recorded as a function of
time at 380nm excitation and 440 nm emission wavelengths set for 0.100 integration time with
600 photomultiplier tube (PMT HV) for 300 seconds at 37℃. To detect initial activity of the
protein, 50 uL of refolded procruzain was added to 2 mL of activity buffer containing 30 uM of
the fluorogenic substrate N-carbobenzyloxy-phenylalanine-arginine-7-amino-4-methyl coumarin
(Z-F-R AMC, BACHEM), 10 mM DTTred and 100 mM sodium acetate (Sigma) at pH 5.5. It was
expected that refolded procruzain would exhibit little to no activity prior to activation as indicated
by a lack of fluorescence emission.
Previously described activation methods21 were ineffective in producing workable
quantities of active enzyme therefore refinement of the protocol was necessary. The refolded
protein was mixed with 1:1 2X activation buffer (200mM NaCH3COO, 1.8M NaCl, 10mM DTTred
and 10mM EDTA, pH 5.2) and incubated at 37℃ for 2 to 4 hours. 50 uL aliquots of activation
mixture was added to 2 mL of activity buffer and applied to the fluorimeter every 30 minutes to
check activation progress. The test samples were lyophilized and analyzed on a 15% SDS-PAGE
and compared to a Fisher Bio-Reagents EZ Run protein ladder to visualize the amount of
procruzain remaining in the sample over the collected timepoints. As maximum activity was
observed, the mature enzyme was inhibited with a final concentration of 10 uM leupeptin or 1 uM
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E-64 (Sigma), a reversible cysteine protease inhibitor, to prevent self-digestion of active cruzain.
Previous work shows the active protein has a molecular weight of 26.5 kDa21,42.
After activation, additional impurities were removed by reverse phase HPLC a Discovery®
BIO Wide Pore C5 Column (Sigma) column eluted with a propanol gradient (0-60%) or ion
exchange chromatography (Mono Q column, GE Healthcare) eluted with a NaCl gradient pH 6.5
(0-1M). High salt concentration can affect protein affinity to the column therefore the sample was
desalted using gel filtration on a G-25 column (GE Healthcare), filtered with a sterile 0.22 um
syringe filter and immediately applied to HPCL or IEX columns. Ultra-pure cruzain was obtained
by applying to a gravity column containing 1 gram of thiopropyl sepharose resin (GE Healthcare)
equilibrated with activation buffer lacking DTTred, eluted with 25 mM DTTred at pH 5.6.
Purification of cruzain by revers phase HPLC was done by applying 1.5 mL (35 uM) of
the filtered protein to a C5 (Sigma) column with a 0 to 60% n-propanol gradient in 0.1% formic
acid48 at a flow rate of 0.3 mL/min detected at 280 nm. Purification using ion exchange
chromatography was done by applying the desalted sample onto a Mono Q anion exchange column
(GE). The protein was eluted with a 0 to 1 M NaCl gradient at pH 5.6 and a flow rate of 1.0mL/min
detected at 280nm. The sample was collected from C5 column, concentrated with a MilliporeSigma™ Amicon™ Ultra-0.5 centrifugal filter unit, lyholized and run on 15% SDS-PAGE to
determine column retention times of cruzain and procruzain. Samples collected from the anion
exchanger, Mono-Q, were desalted on a G-25 column at 1.5 mL/min flow rate with 1% formic
acid before lyophilization.
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2.4

Results and discussion

2.4.1 Transformation of E. coli subcloning and expression strains
The E. coli strains used for expression and subcloning produced a high level of
transformation efficiency. To prevent overgrowth of colonies, transformed cells spread on LB
agar plates were restricted to an incubation period 14 hours. Overgrown colonies were not
further utilized since they are not properly isolated and often grow into other colonies which can
lead to inactivation of the antibiotic resistance genes. Production of small satellite colonies
stemming from overgrown colonies can evolve to survive in the presence of antibiotics even if
they lack the plasmid that codes for resistance. These satellite colonies will not express the
protein of interest. To prevent this from occurring, small colonies were incubated for a
maximum of 14 hours. No green fluorescent protein (GFP) or other florescent tags were coexpressed with the procruzin to maintain the integrity of the protein structure. Though very
useful in identifying successfully transformed cells, GFP tags were omitted because mature
cruzain may degrade the tag and create unwanted waste increasing the number of purification
steps while reducing yield.
Chemically competent cells were used for both types of transformation. It is believed
that the calcium in the buffer prepares the cell for uptake of the plasmid by making the bacterial
cell membrane more permeable. Heat shock also increases permeability of the cell however
heating at a temperature higher than 42℃ or for a long period of time may kill the cells giving
less expression product. To reduce the need for frequent transformations, cells were stored in a
glycerol stock. Glycerol protects the cells that are being stored at -20 and -80℃. Aliquots of
purified DNA and transformed cells were stored in individual sterilized cryogenic tubes to
prevent freeze-thaw damage that large stock solutions may undergo.
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2.4.2 Expression and Purification of Procruzain
The inactive protein was expressed as a proprotein containing the pro- and catalytic
domains. The genetic organization of the non-recombinant protein is shown in Figure 23. The cterminal extension is not required for catalytic function or folding and the signal peptide is not
compatible with prokaryotic expression systems therefore the two domains were omitted from the
DNA construct. The prodomain was degraded by autoactivation under the appropriate conditions
(see activation). Table 4 provides the expected molecular weights of each domain provided by a
molecular

weight

calculator

based

on

the

amino

acid

sequence

(http://www.bioinformatics.org/sms/) discovered by Eakin et.al.21

Figure 23: Sequence organization of recombinant procruzain
The protein used in our studies lack the c-terminal extension
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of

the

protein

Table 4: Estimated molecular weights of cruzain domains.

Procruzain was expressed as an inclusion body and was solubilized sonification in addition
to lysis with 8M urea. The addition of sonification to our method based on published protocols
helped improve our yield. A significant amount of proenzyme with high purity was obtained
(Figure 24) after lysis and purification. The fractions were pooled, divided and stored for future
studies. Figure 25 is a picture of the SDS-PAGE results of a second expression and purification
off a nickel chelation chromatography eluted with 2mL aliquots of elution buffer. A dominant
band believed to be procruzain can be seen in both figures. This band is estimated to have a
molecular weight of approximately 36 kDa which correlates well with the estimated molecular
weight of procruzain given by the molecular weight obtained from the literature42 (Figure 23, Table
4). In Figure 25 a faint band above the 25 kDa marker may represent a very small quantity of
active enzyme. In fact, some gel results showed a faint band near 10kDa possibly representing
autocatalytic degradation product, the prodomain.

For use in subsequent experiments, no

additional purification was necessary. The pH of the samples was maintained at pH 8.0 and
immediately stored at 20℃ to prevent full activation. Because of the possibility that cruzain is coeluted from the column, folding studies were conducted soon after to prevent degradation of the
proenzyme.
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Figure 24: Procruzain purification results.
12% SDS-PAGE stained with Coomassie blue results of elutions off the NiNTA colunm, Elution 1 (E1) to
Elution 12 (E12) collected from the nickel column. A BioRad molecular weight maker was used to estimate the
molecular weight of the expressed protein. Molecular weights are labeled with arrows.

Figure 25: Additional procruzain purification results.
12% SDS-PAGE stained with Coomassie blue results of elutions off a NiNTA colunm, Elution 1 (E1) to Elution
14 (E14) collected from the nickel column. This picture shows a slight impurity above 25 kDa Molecular weights
are labeled with arrows.
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To increase purity, 10mM imidazole was added to the buffer used to lyse the cells,
solubilize the protein, and equilibrate the column. Using too much resin can increase non-specific
binding therefore excess protein was applied to the column. A high concentration of urea (8 M)
was added to all the purification buffers (lysis/equilibration, wash and elution) to prevent
precipitation of the protein. Dialyzing the sample for removal of solutes resulted in precipitation
therefore the concentration of the solutes was reduced by dialfiltration.
An activity check was conducted on refolded protein to check for initial activity. The
fluorogenic substrate, N-carbobenzyloxy-phenylalanine-arginine-7-amino-4-methyl coumarin (ZPhe-Arg-AMC) is cleaved at the amine group of the arginine residue by the cysteine protease,
which releases the AMC group. Fluorescence is caused by the conjugated pi system of electrons,
resulting delocalization allowing electrons to absorb energy and reach an excited state where
fluorescence is emitted. Within in the substrate, the fluorogenic AMC group is quenched buy the
arginine residue in the dipeptide substrate, however once cleaved by the protease, fluorescence can
be observed.

Figure 26 is the structure of z-Phe-Arg AMC with the fluorogenic region

highlighted. Fluorescence released by the cleavage of the peptide at the AMC region was detected
with a fluorescent spectrophotometer at an absorbance of 380nm and emission at 440 nm.
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Figure 26: Structure of Z-Phe-Arg-AMC
All regions of the substrate are labeled, the fluorogenic region, AMC, is highlighted in green

The results of the fluorescence assay seen in Figure 27. The slight fluorescence may be
due to the presence of small amount of mature enzyme. This information correlates with the gel
picture seen in Figure 26. A light band with approximately 27 kDa in size was visualized on the
gel which could be the producing the slight fluorescence. The enzyme showed a very slight and
not full activity because the majority of the enzyme remains in the inactive zymogenic form until
the optimal conditions for activation are optimized, however after refolding a small amount has
reached maturation. The sample was compared to a negative control containing activation buffer
containing the substrate lacking the protein. The control shows no increase in fluorescence hence
no activity. When compared to active protein (Figure 28), the amount of fluorescence produced
by premature activation (after Ni NTA purification and refolding) is minimal however the presence
of active enzyme, even in a very small amount, can trans-catalyze the maturation of additional
protein over time if left uninhibited or if not stored in conditions that prevent activation.
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Figure 27: Initial activity check of purified procruzain.
The activity of the purified protein was analyzed through fluorescence spectroscopy. Fluorescence was analyzed
at an excitation wavelength of 380 nm and emission wavelength of 440 nm.

Though fluorescence is still detected after refolding, it is very minimal in comparison to
the fluorescence produced by the fully matured enzyme. The graph (Figure 27) shows an increase
in fluorescence over the time assayed to be less than difference of 1 fluorescence volt and often
produces even less of a difference. In comparison, active cruzain gives a difference of over 5
fluorescence volts. The next section will describe the comparison of the activity in procruain and
cruzain.
2.4.3 Activation of Cruzain
Activation was detected by fluorescence detected by the hydrolysis of the fluorogenic
substrate, z-Phe-Arg AMC. Once the maximum amount of fluorescence was observed, an
inhibitor was added to the sample to prevent self-degradation. The fluorescence released from the
hydrolysis of the substrate was significantly larger compare to the activity check done in freshly
purified protein (after refolding). Figure 28 is the chromatogram of the maximum activation
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achieved as well as the inactivation by leupeptin. The maximum activation was achieved after 4
hours of incubation at 37°C which remained constant for up to 6 hours. After 6 hours, the protein
showed a decline in activity due to autodegradation. At 4 hours the protein was highly active
(Figure 28) and incubation with the inhibitor at 37°C rendered the enzyme inactive. A 500uL
aliquot of the protein sample was removed at different time points and applied to electrophoresis
to determine if the active protein possessed the expected molecular weight of active cruzain and
to also visualize the activation progress over time (Figure 29). By the last time point, the protein
was fully activated and the prodomain (approximately 11 kDa) that is believed to cover the active
site of the proenzyme was cleaved (Figure 30). The size difference between the mature and
proprotein along with the results of fluorescence assay are proof that the protein has matured.
Activation of Procruzain

Figure 28: Fluorescence analysis of active and inhibited cruzain
The activity check of mature enzyme (red) is compared to a blank (blue) and enzyme with an inhibitor (green)
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Figure 29: Activation progress
Samples collected at different time points were analyzed on 15% SDS-PAGE. Different time points were
collected to track activation progress. Lane 1: Time = 30 min after initial activation, Lane 2: Time = 60 min,
Lane 3: Time = 120 min, Lane 5: Time = 180 min and Lane 6: Molecular weight marker.

Figure 30: Full activation of cruzain
Activation after 4 hours. Lane 1: MW marker (Fisher EZ-Run ladder). Lane 2: active cruzain
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After activation, most of the procruzain matured to the active enzyme. The gel seen in
Figure 29 shows a decrease in the 36 kDa proenzyme and an increase in cruzain at approximately
27 kDa. Along with the fluorescence assay, the result show that the prodomain has been removed
from the proenzyme. Since the prodomain is small (11 kDa) and subject to additional degradation
by the mature enzyme, it is difficult to visualize it on SDS-PAGE however very faint bands can
be seen above the 11kDa protein marker in the ladder and a band is also visible near 15 kDa. These
may be degradation products that remain after the autocatalytic activity of the enzyme is complete.
In previous activation attempts, very little mature enzyme was produced with protocols
found in the literature28. The amount of mature protein produced was less than the nanogram range
and only resolved with silver staining after running a 12% gel. To improve our yield, we optimized
the conditions of expression and activation. The protein was expressed as inclusion bodies and a
high concentration of urea was added to harvested cells to help dissolve the inclusion bodies and
lyse the cells. To release a higher concentration of protein from the cells, sonic waves were applied
to the cells containing lysis buffer. In addition, 10 mM imidazole was added to the lysis buffer to
prevent non-specific binding on the nickel column. Activation methods using different conditions
were conducted to determine the optimal conditions for activation. Concentrations of DTTred, urea
and sodium chloride were manipulated. The optimal pH was found to be between 5.2 and 5.5 and
activation was initiated at a pH of 5.3. Though the role of the buffer is to maintain pH, over time,
the pH of the protein drifted due to the maturation of the acidic proteinase, therefore pH was
checked every hour to ensure that the pH was maintained at the optimal range. Procruzain is
moderately hydrophobic therefore a high concentration of sodium chloride was added to the
activation buffer to prevent aggregation of the protein. They high hydrophobic index of proruzian
is also the reason dialysis was avoided. Approximately 10 mg of procruzain was produced from
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1L of cell culture and 100 ug of mature enzyme was produced after activation. Both procruzain
and cruzain were stored at -20℃ and used for kinetic studies describes in the next chapters.
High concentrations of sodium chloride and urea were used in buffers at all stages of
expression and purification to prevent insoluble aggregates from forming during purification. The
auto-catalytic activation of cruzain is not well understood however the process is highly pH
dependent. Many cysteine proteases are often localized in lysosomes where the pH is often below
physiological conditions. Recent studies conducted on the mechanism of activation of the
cathepsins suggest the activation is both a unimolecular and a bimolecular process meaning the
initial activation is done by the zymogen alone which in turn, activate other inactive enzymes in a
chain reaction. A low pH disrupts salt bridges within the pro-domain of the protein by protonating
carboxylate groups which can cause change in structure that prevents hydrophobic interactions.
The changes in tertiary structure likely removes the pro-domain from blocking the active site,
allowing the active site to cleave the prodomain. Figure 31 illustrated the significance of pH on
the tertiary structure and enzyme activity of falcapain-2, a papain family cysteine protease found
in Plasmodium falciparum parasites.29
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Figure 31: Interactions between pro-domain and catalytic domain of falcapain-2
The green dotted circle highlights the salt bridges allowing the pro-domain to black the active site. Reducing
the pH disrupts these salt bridges and as a result the pro-domain is cleaved.29

Reduced and native protein were each applied a reverse phase Discovery BIO Wide Pore
C5 column (5um pore size, Sigma) and an ion exchange column to determine retention times for
future studies. Figure 32 is the chromatogram of the purification using the HPLC C5 column.
Initially, a C18 column was used to attempt separation of the peaks, however it was difficult to
elute the protein off the column due to strong interactions of the hydrophobic residues exposed on
the surface of the enzyme with the column. Procruzain and mature cruzain were then applied to
the C5 (less hydrophobic) column which was eluted with a gradient of n-propanol. The peaks
were collected and run on 15% SDS-PAGE, Figure 33. It was difficult to separate reduced from
native enzyme however we were able to identify the peaks on the chromatogram. With further
manipulation of the method, we plan to visualize all the intermediate species during oxidative
folding and applying aliquots over of the 24 hours to HPLC to calculate folding rates constants.
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Time (min)

Figure 32: HPLC Chromatogram of active cruzain.
The small peak is the native protein that has a slightly shorter retention time than the reduced form of cruzain.

Figure 33: Purified Cruzain on HPLC C-5 Column
Lane 1: Empty well, Lane 2: Molecular weight marker, Lane 3: HPLC purified native cruzain, Lane 4:
Empty well, Lane 5: Concentrated HPLC purified native cruzain, Lane 6: HPLC purified reduced cruzain.
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Figure 34 represents the superimposed chromatogram of the purification of native and
reduced cruzain by ion exchange chromatography, Mono Q anion exchange column. Native and
reduced cruzain elute at similar times and are difficult to separate. Reduced and native
procruzain had similar retention times. The gel picture, Figure 35, is the large peak collected
from the HPLC and run on 15% SDS-PAGE proving the large peak obtained from the column is
mature cruzain. The reduced peak was also run and visualized on a gel.

Time (min)

Figure 34: Purification by anion exchange chromatography
The red peak is reduced cruzian and the purple peak is native cruzain.
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Figure 35: Purification of CZP by anion exchange chromatography
After separation on IEX, the samples were collected and applied to a 15% SDS-PAGE. Lane 1 cruzain before
purification. Lane 2 cruzain after purification on a Mono Q column.

Purified protein was then collected and used for studies that are discussed in the next
chapters. Several challenges expressing, purifying and activating the enzyme were experienced
however, the method of purification and activation were refined to obtain a higher yield of
protein. The high degree of hydrophobicity of the protein contributed to the formation of
insoluble aggregates thus a loss of protein. These aggregates were prevented by keeping the
sample in an 8.0 M urea buffer at pH 6.5 until the was to be used. While further purification of
mature enzyme was not necessary, the samples were applied to the HPLC to determine retention
rates for oxidative protein folding studies. The goal was to compare folding rate constants of
procruzain and cruzain and determine the role of the prodomian in protein folding however this
method was not effective therefore a novel method was developed to overcome these challenges.
Several expressions were done successfully and the protein produces was used to refine the
methods and subsequent expression were used for protein folding studies.
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CHAPTER 3
DEVELOPMENT OF A NOVEL METHOD TO DETERMINE FOLDING
RATES
3.1

Specific Aim

Specific aim two: To develop a novel technique to compare the folding rate of procruzain and
cruzain.

3.2

Background
Traditionally, folding rates are calculated by UV spectroscopy. For thiol containing

proteins, the rate limiting step during oxidative folding is the formation of disulfide bonds.
Proteins that do not contain disulfide bonds often fold in milliseconds.55 In comparison, those that
do contain disulfide bonds will fold slowly. Within the cell, oxidizing agents and chaperones assist
with folding to prevent aggregation and malfunction. The more disulfide bonds a protein contains,
the longer it will take to obtain its native structure due to constant isomerization of the disulfides
until the native structure is achieved. We can utilize this rate limiting step to help us detect folding
progress over time, in vitro.
A denatured protein lacking disulfide will achieve its correct 3-dimensional structure as
soon as denaturants are removed (often by dilution). The amount light absorbed by the protein
will change, often decreasing as hydrophobic residues with aromatic rings evade an aqueous
environment. The folding rates can be calculated by analyzing the absorbance of a protein at
280nm assuming the protein contains tryptophan residues (and phenylalanine and tyrosine to a
lesser extent). Intrinsic tryptophan fluorescence can also be used to detect protein folding at 280
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nm excitation and 350 nm emission. Exposed tryptophan quenches fluorescence therefore,
florescence should increase as the protein folds depending on the identity of the protein.65
A method described by Narayan et. al66-68 utilizes disulfide bond formation as a rate
limiting step to calculate folding rates. The method collects aliquots at different time points during
oxidative folding until the folding is complete. The aliquots collected are then applied to an HPLC
and elution off a reverse phase column (often C-18) is detected at 280 nm. Reduced and native
proteins often have different retention times. The reduced protein is retained on the column longer
due to exposure of hydrophobic resides, while native protein will have less hydrophobic resides
available to interact with the column. Over time, the peak representing the quantity of reduced
protein will decrease and the native peak will increase. In vitro conditions are made to mimic the
cell however the cell is much more efficient at oxidative folding provided individuals are healthy.
The data obtained from kinetic studies can provide valuable information about the protein such as
structure, enzyme activity and malfunction.
Though the method previously describe is exceptionally useful in observing oxidative
folding, highly hydrophobic proteins will not benefit from this type of study. Protein aggregation
can be one problem while strong attraction to the column can is another. Finally, sensitivity may
also pose a problem due to low concentration of proteins. Even though the method for activation
of cruzain was refined (Chapter 2), precipitation of the both procruzain and cruzain occurred,
therefore a method with high sensitivity is was developed.

Equally important, procruzain and

cruzain do not elute off a of reverse phase chromatography or ionic exchange columns easily
therefore a new method was developed
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3.3

Materials and method: Determination of folding rates

3.3.1 Oxidative Folding of Ribonuclease A
A model protein with a fully known folding patter was used to develop a novel method for
the determination of folding rates. Bovine Pancreatic Ribonuclease A (Sigma, molecular biology
grade, >70 Kunitz) was reduced and denatured with a reducing buffer (8 M guanidine HCl, 30 mM
DTTred and 100 mM Tris buffer pH 8.0) by incubating 2mg of ribonuclease A in 5 mL of reducing
buffer and incubated for 45 minutes at room temperature. Refolding was prevented by decreasing
the pH to 4.0 with an acid quench of glacial acetic acid (20 uL). The reduced protein was dialyzed
in a 3.5 kDa cellulose dialysis tube (Spectra Por) against 0.010 M acetic acid buffer under slight
agitation at 4℃ for 3 buffer changes. After dialysis was complete, the sample was filtered with a
0.22 um syringe filter (Whatman) and the concentration was calculated using Beer’s law by
analyzing at an absorbance of 280 nm.
Reduced RNase A (30uM final concentration) was added to a refolding buffer containing
0.50 M urea, 5% glycerol and 125 mM arginine at pH 8.0 for a total volume of 10.0 mL. 2.0 mL
of the reaction mixture was separated for HPLC studies conducted in parallel to the novel method.
250 uL aliquots were collected every hour for 20 hours. These samples were reacted with Ellman’s
reagent as described below to determine the extent of folding for each time point.
Oxidative folding was carried out in parallel on the HPLC using an Agilent HPLC and
autosampler in parallel to the method described above to verify the results of the novel method.
Reduced and native RNase A were run on a reverse phase HPLC C-18 (Sigma Discovery) column
to determine retention times and extent of folding over time. 100 uL samples were run on the
HPLC every hour for 16 hours. The time points were eluted with a 0-100% acetonitrile gradient
in trifluoroacetic acid at a flow rate of 0.40mL/min. The area under the peaks were calculated and
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plotted versus time and the equation of the line provided the rate constant. The rate constant
obtained by the novel method was compared to the HPLC method to determine validity.

3.3.2 Procruzain and cruzain denaturation and reduction
To reduce the protein reducing buffer (8 M urea, 30mM DTTred and 100mM Tris buffer
pH 8.0) was added to the protein and incubated at 37℃ for 2 hours. After the 2-hour incubation
period, the pH was decreased to 4.0 to prevent refolding. The reducing agents and salts were
removed with a G-25 size exclusion column by eluting with 20 mM formic acid at pH 4.0. The
protein concentration was determined with the Bradford assay (BioRad) and bovine serum
albumin as the standard. The absorbance was recorded at 595 nm and the concentration of the
protein was calculated with the Beer-Lambert law then stored at -20˚C. The increasing
concentrations of BSA were used for the standard curve were: 0.125 mg/mL, 0.500 mg/mL,
0.750 mg/mL, 1.00 mg/mL, 1.50 mg/mL and 2.00 mg/mL. The removal of the solutes from the
protein lead to aggregates therefore the processing of the protein was be done carefully to
prevent loss of yield. The protocol above is the most effective in removing the denaturing and
reducing agents while preventing precipitation of the protein. Dialysis was avoided when
possible, however when it was the only means for removal of solutes, dilute sample was placed
in 3-5 kDa a cellulose membrane dialysis tube (Spectra Por) against an acetic acid/acetate buffer
at pH 4.0 (3.0 L) with three changes of buffer once every 8 hours at 4℃ under slight agitation.
The figure below is a diagram of the denaturing/reduction process.
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Figure 36: The reduction of native protein
Reducing buffer was added to the protein to denature and reduce procruzain and cruzian.

3.3.3 Ellman’s test for determination of folding rates of procruzain and cruzain
Both procruzain and cruzain were reduced and refolded to determine the rate of folding
and to identify any stable intermediates during regeneration. Regeneration devoid of oxidizing
and reducing agents was essential since DTNB reacts equally with both. In place of oxidizing
agents like glutathione or DTTox, refolding was done by adding a low concentration of
chaotropic agents and salts. The proteins were then allowed to fold by air oxidation.
Regeneration was done by adding 1:1 refolding buffer containing 250 mM L-arginine (Sigma),
100 mM Tris HCl (Sigma), 1mM EDTA (Fischer Scientific) 1 M urea (Sigma) and 20%
Glycerol (Fischer Scientific) to the desalted, reduced and denatured protein for a final
concentration of 30 uM and the pH was adjusted to 8.0. The protein was exposed to air and
refolded at room temperature for 15 hours under slight agitation. 500 uL aliquots were collected
and stored at -20℃. Oxidative folding was analyzed with fluorescence spectroscopy and with
liquid chromatography.
500 uL time points were reacted with excess Ellman’s reagent, 0.4 mg/mL final
concentration, in a reaction buffer (100 mM Tris HCl 1 mM EDTA pH 8.0) and incubated at
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25℃ for 15 minutes. After the incubation period, the absorbance was taken at 412 nm (molar
extinction coefficient 14,500 M-1∙ cm-1) on a Genesys 10 Visible Spectrophotometer. The
folding rate was calculated by finding the slope of the line of best fit when plotting the
absorbance versus concentration. Oxidative folding lacking oxidizing agents was conducted for
the mature and the proenzyme. The average of the folding constants was calculated and
compared to determine the role of the pro-domain in oxidative folding. Figure 37 is a schematic
of the reaction and the protocol developed to determine folding rates constants for cruzain and
procruzain.

Reduced
Protein

Figure 37: Schematic of Ellman’s test for thiol concentration determination
Top: DTNB mechanism. Bottom: Reaction porotocol. Bottom schemic of folding analysis protocol.
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3.3.4 Expression of the protein prodomain
The prodomain of procruzain was expressed, purified and refolded as described in 2.3.32.3.4 of this manuscript. The protocol used to express, purify and refold procruzain and the
mutant C25A were followed without any modifications. Removal of solutes was done with
dialysis against phosphate buffered saline (PBS) pH 8.0 with a 3.5 kDa Fisherbrand regenerated
cellulose dialysis tubing. After three dialysis changes, purity was visualized by 18% SDS-PAGE
against a Fisher BioReagents EZ-Run Rec protein ladder and stained with Coomassie brilliant
blue R250 as described in section 2.3.4. The dialyzed product was concentrated with a GE
Healthcare Vivaspin 20 Sample Concentrator centrifugal unit at 4000 rpm and 4℃. Figure 38 is
a schematic of the protocol used to prepare the proteins. The Bradford assay was used to find the
concentration of the prodomain.
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Refold, dialyze and concentrate
pH 8.0

Figure 38: Expression protocol of the proteins used in this study
BL21, M15 or DH5α cells were transformed, plated and grown at 37℃ with the appropriate antibiotics.
Purification was achieved with a Ni-NTA chelating column. The pure protein was dialyzed and concentrated.

3.3.5 Role of Prodomain in Oxidative Folding
To determine if the pro-region is necessary for the mature protein to regain its native
conformation and activity, regeneration and activity was simultaneously detected by
fluorescence spectroscopy. The reduced and denatured enzyme (section 3.3.3 for denaturation
and reduction method) was desalted on a G-25 (GE Healthcare) column eluted with 1% formic
acid at pH 4.0 and was quickly added to a refolding buffer containing the substrate to a 30uM
final concentration. The refolding buffer containing 500 mM L-arginine (Sigma), 200 mM Tris
HCl (Sigma), 2 mM EDTA (Fischer Scientific) and 40% Glycerol (Fischer Scientific) was
diluted 1:3 with ddH2O. The substrate Z-Phe-Arg AMC and reduced cruzain was added to the
buffer at final concentration of 50 uM and 30 uM respectively (2 mL total reaction volume). The
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sample was placed in a quartz cuvete (Fisher scientific) and inserted in the fluorimeter with an
excitation set at 380nm and emission at 440 nm. Fluorescence was detected at 37℃ over a
period of 16 hours.

A negative control lacking mature enzyme was also run to determine if the

reagents used in the reaction were fluorogenic.
The reaction was repeated with the addition of expressed and purified prodomain to the
reaction mixture in equal concentrations (30 uM) to reduced mature cruzain to see if the folding
rate changed.

3.4

Results and discussion

3.4.1 Ellman’s test for determination of folding rates
The data obtained from traditional oxidative folding methods was compared to the data
obtained from the novel methods to test the validity.

Because the folding pattern of RNase A is

well known and the folding rates have been determined,66-68 it was used a model protein. As
opposed to the method previously used, oxidative and reducing reagent were completely omitted
due to reactivity with DTNB. The oxidative folding results from the HPLC were as expected
and the folding rate extrapolated from graphical data. The chromatogram in Figure 39 show the
HPLC results of the regeneration of RNase A using an absorbance of 280nm. Several time
points were selected and the graphs superimposed to visualize the folding progress. In general,
native protein is eluted first from the column and the reduced protein follows second. The
separation of native and reduced protein was achieved by choosing a C-18 column and refining
the method. The native enzyme binds with a reduced affinity because less hydrophobic amino
acids are exposed to interact with the hydrophobic column. On the other hand, the hydrophobic
residues are exposed when the protein is reduced and denatured making them available for
interactions with the column. The amount of reduced RNase A (second peak) decreased over
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time producing more protein in its native state (first peak). The area under the curve was
calculated and converted to concentrations with Beer’s law.

Figure 39: Regeneration of RNase A
Chromatograms of select time points super imposed to show regeneration over 20 hours. Blue: Time 0, Red:
Tine 6 hours, Green: Time 16 hours after initiation of reaction. N=native, R=reduced.

To test the validity of our method with Ellman’s reagent, we compared the results
obtained from traditional oxidative folding experiments to the results obtained with our novel
method. To determine if the protein was folding over time, we reacted an aliquot of each time
point collected during oxidative folding with Ellman’s reagent and recorded the absorbance at
412 nm. The absorbance was plotted versus the time to demine a folding rate. As protein
folding occurs, less thiols are available to react with DTNB, providing a decrease in intensity of
the yellow color (due to free NTB2+). Though spectroscopy provides us with absorbance, the
decrease in color intensity can was observed. Figure 40 is a photograph of the results showing a
decrease in yellow color over time.
68

Figure 40: Results of Regeneration Detected with Ellman’s Reagent
The intensity of the yellow color at T1 (1 hour after initiating folding) is deeper that T10 (at 20 hours) when
regeneration was complete.

This data was compared to the results obtained from the HPLC to determine the validity
of the novel method. The folding rates were calculated by taking the area under the curve of
each peak from individual time points provided by the HPLC chromatograms. Protein folding
follows first order kinetics therefore the data was plotted as the natural log of the fraction of
native protein formed over time. The calculations used to find the points plotted can be found in
Table 5.
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Table 5: Calculating the fraction of native RNase A formed
Time

Time

Native (N)

Reduced

N+R

N/N+R

((1-n)

ln(1-n)

Point

(min)

(area of first

(R)

(total

=n

(fraction

(1st

peak on

(area of second

protein)

(fraction

of

order

chromatogram)

peak on

of native)

reduced)

kinetics)

chromatogram)
T0

M0

N1

R1

X1

Y1

Z1

F1

T1

M1

N2

R2

X2

Y2

Z2

F2

T2

M2

N3

R3

X3

Y3

Z3

F3

T3

M3

N4

R4

X4

Y4

Z4

F4

T4

M4

N5

R5

X5

Y5

Z5

F5

T5

M5

N6

R6

X6

Y6

Z6

F6

T6

M6

N7

R7

X7

Y7

Z7

F7

T7

M7

N8

R8

X8

Y8

Z8

F8

T8

M8

N9

R9

X9

Y9

Z9

F9

T9

M9

N10

R10

X10

Y10

Z10

F10

Since protein folding is believed to occur under first order kinetics the natural log of 1-n
was graphed versus the time in seconds. Figure 41 is an example of a graph of the plotted points
lnR (reduced fraction) versus time in minutes. The experiment was replicated at least 6 times
and an average of the rate constants was obtained. Other proteins such as lysozyme were used to
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test the validity of the method as well (data not shown). The equation of the line provided the
folding rate constant which is equivalent to the slope and the R2 value shows the correlation
value of the line. This data was compered to data obtained from the method developed with
Ellman’s reagent to test the validity of the novel method (Figure 42) which was run in parallel

Figure 41: Traditional Regeneration Method

The folding rate constant was obtained from studied done directly on the HPLC
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Figure 42: Novel Method for regeneration

Ellman’s reagent was used to determine the fraction of folded protein at different time points

Upon conducting several trials of each method that were run in parallel to each other
using the same source of reaction mixture, it was determined that novel method produced similar
results to the method that employs liquid chromatography and UV absorbance. The Table 6
provides an average of the folding rate constants using the HPLC method in comparison to the
novel method including standard deviations for each.

Table 6: Comparison of folding rate constants obtained from the two methods

Method

Avg Folding Constant

Deviation

RNase A HPLC

0.00520

8.983×10-4

RNase A Ellman’s

0.00480

6.379×10-4
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A slight difference in folding may be due to the storage and preparation of the samples.
Aliquots that were collect at different times were quickly frozen (flash freeze with liquid
nitrogen) and stored at -80℃ until all time points were collected. The samples were allowed to
thaw for 15 minutes. DTNB was added and incubated at room temperature for an additional 15
minutes to allow the reaction to occur. A yellow color was observed and the intensity
(absorbance) of the yellow color decreased over time due to less thiolates available to react with
DTNB as the protein folds.
Because it is difficult track regeneration of procruzain and cruzian by HPLC and UV
spectroscopy, we detected the folding progress with Ellman’s reagent to determine the
concentration of thiolates remaining at different times during regeneration. Ellman’s reagent or
DTNB (Sigma) is a compound that contains a disulfide bond and creates a mixed disulfide with
free thiolates at pH 8.0. In the reaction, DTNB (5,5'-dithio-bis-[2-nitrobenzoic acid]) becomes
reduced and releases TNB2- which can be detected by spectroscopy in the visible range. With
high concentration of thiolates for example at time zero when a protein is fully reduced, an
intense yellow color is observed and the free due to a high concentration of TNB2- (absorbs at
412 nm) released from DTNB. The amount of TNB2- released is proportional to the number of
thiolates present according to Beer’s law. The absorbance due to the presence of free TNB2(ε=14,150 M-1cm-1) decreased over time as the protein folds.69
There are several benefits to using this method to determine folding rates. First, highly
hydrophobic proteins tend to precipitated when desalted and cannot be solubilized for use in
experiments giving a low yield of available protein. Another benefit is that the method has a
high sensitivity. The reaction was conducted with protein at 10-30 uM. Finally, the method is
cost effective. Reagents are economical and a visible spectrophotometer can be found in most
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laboratories, whereas the UV spectrophotometer is much more costly. One flaw of the method is
that it is more labor intensive than the traditional method. Most HPLC are equipped with an auto
sampler and the reactions can be set up to take time points automatically, every hour for a long
period of time. Our method requires and individual to physically remove aliquots at different
time points store them and conduct Ellman’s test as soon as folding is complete. Time
management is essential since proteins lacking oxidative reagents can possibly take days to fold.
This method would not be effective for calculating folding rates constants of proteins containing
more than 5 disulfides as it may take long to fold the protein without oxidizing agents.
It was previously believed that proenzyme do not achieve a native conformation once the
pro-region is cleaved however the results (Figure 41) indicate that both procruzain and mature
cruzain will fold over time. Studies on cathepsin and subtilisin have concluded that the
prodomain assists in the formation of the native structure in vivo, however it has not yet been
determined if the pro-region is required.70, 71 In this work we show that the prodomain is not
required for regeneration and that procruzain and cruzain have slightly different rates of
regeneration probably due to an additional cysteine found in the prodomain. Figure 43 provides
the graphical results for one of the trials of the regeneration of both the mature and the
proenzyme. Mature cruzain had a faster rate of regeneration as shown by the slope of the line.
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Figure 43: Regeneration results with Ellman’s reagent

Comparison of the folding rate of procruzain was compared and cruzain

The average of the trials along with standard deviations are provided in Table 7. Cruzain
is slightly faster at reaching the native conformation in comparison to procruzian. Procruzain
contains an additional cysteine in the pro-region that can interfere with disulfide bond shuffling,
taking longer to reach the native state.

Table 7: Comparison of folding rates of procruzain and cruzain
Protein

Avg Folding Constant

Deviation

Procruzain

0.00095

3.923×10-5

Cruzain

0.0011

1.342×10-4
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The folding rate constant at near standard conditions, was similar for each trial and the
results of all trials showed that cruzain folded slightly faster than procruzain.
3.4.2

Production of the Prodomain

The prodomain was expressed with the exact same protocol that produced procruzain.
The prodomain was refolded and dialyzed with less precipitation when compared to dialysis of
procruzain therefore this was the preferred method for the removal of salts. The results were
visualized on an 18% gel. The increased concentration of acrylamide was used to reduce run-off
of the protein by allowing the small protein to migrate slowly through the gel. Figure 44 is the
results of the expression and purification given by SDS-PAGE.

Figure 44: Results of the Prodomain purification
Lane 1: Empty well. Lane 2: Elution 2. Lane 3: Elution 4 off the Ni-NTA column. Lane 4: Protein ladder.

The dominant band that can be seen on the gel has a molecular weight between 10 and 15
kDa. There is a faint band that can be seen above 20 kDa which may represent a dimer between
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the prodomains though the amount was negligible. The band was no longer visible in subsequent
elutions off the column. The purified prodomian was used to determine the impact on catalytic
activity on protein folding of the mature enzyme.
3.4.3

Dependence of the prodomain on protein folding

In addition to regeneration with Ellman’s test, we detected the folding progress with
fluorescence spectroscopy over several hours to see if the protein would refold and regain its
activity. It is believed that proteases expressed as zymogens will not gain their full activity or
properly fold since the prodomain exhibits endogenous chaperone-like activity. The results
below show an increase in florescence of the reaction mixture over time as compared to the
negative control (blank). The blank does not exhibit fluorescence so we can assume that all
fluorescence provided by the reaction mixture is due the activity of cruzain. It can be concluded
that the protein can regain the native conformation even in the absence of the prodomain, and
more importantly, regains the protease catalytic activity.
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Figure 45: Regeneration of reduced and denatured cruzain
Regeneration of previously activated reduced and denatured enzyme was detected by fluorescence
spectroscopy over 16 hours.

The mature enzyme was allowed to fold in the presence of the prodomain to verify the
prodomain was not needed for regeneration and function. Equimolar of purified prodomain was
added to reduced cruzian and allowed to fold over the course of 16 hours. Regeneration and
activity were detected by the release of fluorescence of the fluorogenic substrate z-Phe-Arg
AMC. The figure below shows that activity decreases when the purified prodomain is added to
the regeneration mixture. It seems that once the prodomain is added to cruzain, it actually
impedes folding and inhibits the enzymatic activity. Though the peptide bond between the
mature enzyme and the prodomain does not exist, some of the interactions made may block
folding and catalytic activity. When observing the mixture after the reaction was complete, a
slight precipitation was visible. This could mean that the prodomain prevented the protein from
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folding and caused the protein to aggregate, greatly reducing the amount of refolded active
enzyme.
Another reason a decline in fluorescence could have occurred is that the enzyme may
hydrolyze the prodomain in addition or in place of the fluorogenic substrate as it enters the
reaction mixture. The prodomain contains several arginine residues at which the enzyme can
catalyze degradation. This activity would not be visible on the spectrofluorometer due to the
lack of fluorogenic groups on the prodomain. The enzyme may have a higher affinity for the
prodoamin than z-Phe-Arg AMC.

One way to verify if the prodomain attaches to the mature

enzyme through non-covalent interactions would be to run the samples on a native gel under
non-denaturing conditions however proving this by electrophoresis proved to be difficult.

Figure 46: Catalytic Activity of Cruzain after the Addition of the Prodomain
The yellow line is the blank with substrate and prodomain but no substrate. The green line is the enzyme
added to the substrate with the prodomain. The pink line is the enzyme with substrate lacking the prodomain
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Work conducted on proenzymes such as the procathepsins and prosubtilisin suggest that
the prodomain acts as an intramolecular chaperone and is essential in protein folding. Because
cruzain regains activity when regenerated after being reduced and denatured, we can conclude
that the correct conformation can be achieved without the prodomain. It can also be concluded
that free prodomain may actually inhibit the mature enzyme. The role of the prodomain in the
folding of procruzian is studied in the upcoming chapters.
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CHAPTER 4
EXPRESSION OF PROCRUZAIN WITH STURCTURE STABILIZING
MUTATIONS
4.1 Specific Aim
To determine the role of the prodomain in conformational folding of procruzain by
identifying structural stabilizing residues with in the prodomain.

4.2 Background
As previously mentioned, the prodomain of zymogenic enzymes is believed to play a
significant role in protein folding and is essential to regulation of enzymatic function65.
Enzymatic activity is gained by the autocatalytic cleavage of the prodomain. Once cleaved, the
prodomain may undergo additional degradation to prevent inactivation of the mature enzyme29.
Though not well understood, it has been proposed that cysteine proteases contain a highly
conserved catalytic triad, in addition, residues near that catalytic site may also interact with the
proregion to achieve the catalytic function. These interactions are essential to regulation.
Interestingly, the prodomains different classes of proteases differ from family to family however
differences may even exist within a family. The pro-regions span from 30 amino acid residues
long to over 200 residues long. Some have several alpha helical regions while others very few.
Procathepsin-B contains an occluding loop that may help regulate enzymatic activity, while
procathepsin-L lacks this loop. Procathepsin-B contains two short alpha helix domains while the
alpha-helix found within procathepsin-L are significantly larger. Figure 45 compares the
prodomain of procathepsin-B and procathepsin-L highlighting the occluding loop in
procathepsin-B. The occluding loop of procathepsin-B may enhance inhibition of the zymogen
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but is also believed to take part in the exogenous protease activity. This activity is less
prominent in procathepsin-L, which lacks the occluding loop.

Figure 45: Comparsion of the procathpsin-L and procathpsin-b prodomains
Procathepsin-L domain is larger by approximately 33 amino acids and procathepsin-B contains an occluding
loop (purple) that L lacks.30

Most cysteine proteinases reside in the lysosomes of the cell which is an acidic
organelle, therefore the optimal pH for activation is essential for maturation and function. In in
vitro studies, the pH must be maintained between a pH of 4.5 and 5.5 for autoactivation and full
catalytic activity. At a low pH, the salt bridge interactions found between the prodomin and the
active site are disrupted by the protonation of carboxylate containing residues such as aspartic
acid and glutamic acid. Disrupting these interactions can lead the disruption of other prodomainactive site interactions. It has been observed that an interaction of a highly conserved glycine
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residue pushes the c-terminal towards the active site, occludes the catalytic regions and obstructs
activity. A decrease in pH and disruption of salt bridges can cause conformational changes that
allow the c-terminal domain to delocalize from the catalytic site. The catalytic site, being free
from obstruction cleaves the prodomain.72 A crystal structure for procruzain is not available
however modeling studies and point mutations may give us an insight to the interaction of the
prodomain with catalytic domain. If these residues are essential for protein maturation and
function, then they could also be significant to achieving a native conformation as the protein is
being synthesized. Structure stabilizing residues can be targeted to prevent folding before the
protein matures in an effort to combat Chagas disease, an immensely different approach to
inhibiting cruzain’s active site directly with small molecules.

4.3 Methods: Identification of target residues, expression and purification
4.3.1 Molecular modeling and alignment studies
Molecular dynamics on procuzain was conducted to identify structure stabilizing residues
that reside within the prodoamin. Charged amino acid residues were replaced with neutral,
nonpolar residues. Folding and activity of the mutants was compared to the wilt type proenzyme
to determine the role of the mutated residues on protein folding.
Homology studies to identify conserved residues was conducted with a BLAST (Basic
Local Alignment Search Tool)73 analysis using the known amino acid sequence of procruzain.
There are human cysteine proteases such as cathepsins that have significant roles in biochemical
processes and are also implicated in many diseases such as cancer. Homology studies can help us
determine which amino acids are conserved and the effect of mutations on essential human
cysteine proteinases such as the cathepsins.

Another reason for sequencing homology studies is

83

to determine which amino acids are conserved across different species of parasites to target other
disease-causing parasites containing cysteine proteinases essential to parasitic survival.
Since no crystal structure for PCZN has been deciphered yet, a homology modeled of
PCZN was constructed using I-Tasser.74 Inter-protein ionic and hydrophobic interactions were
further calculated by Protein Interaction Calculator (PIC), where salt bridges were assigned when
distance between the two atoms of opposite charge was less than 6Å and side chain-side chain
hydrophobic interactions were also calculated within 6Å distance. The homology-modeled
structure, inter-protein interactions, and residue substitutions were visualized using PyMol
MAESTRO, and CHIMERA software.
4.3.2 Expression and purification
4.3.2.1 Double selection expression
Expression of the mutants each containing a single mutation required a double selection
process. A plasmid pQE-30 containing 6xhistidine-tagged procruzain (WT and mutants) at the
N-terminus was introduced into competent E. coli DH5α for subcloning and into E. coli M15 for
expression (Invitrogen). A modified version of a method previously described in this manuscript
was used produce a high yield of protein. A 5 mL LB culture with antibiotics (amp 100 uM/kan
50 uM) was inoculated with a freshly transformed colony and grown to an O.D.600 of 0.7-0.9.
Grown cells were then inoculated onto a LB/amp/kan plate and grown overnight at 37˚C. From
the transformed plate, 3 colonies were selected inoculate 3x 5 mL LB/amp/kan culture and
grown overnight. at 37˚C. A small-scale expression, described below, was performed for each 5
mL culture. Before induction with Isopropyl-B-D-1-thiogalactopyranoside, IPTG (Fisher
Scientific), cells from each expression were inoculated into a LB/amp/kan plate. The plates were
identified as “colony A”, “colony B” and “colony C”. Expression levels were checked and 3
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colonies from the plate with the highest expression level were selected. The second colony
selection repeated the aforementioned procedure followed by glycerol preservation.
4.3.2.2 Small scale expression
Luria Broth (LB) media (5 mL) was inoculated with one colony from overnight grown
plate and incubated at 37˚C. When the O.D.600 was between 2 and 3, the culture was gently spun
down for 5 minutes at 1500 rpm. The resulted cell pellet was re-suspended into minimal
medium. When the O.D.600 reached around 1.0 cells were induced by addition of IPTG (1 mM)
and incubated at 37˚C for 4 hrs. Expression levels were checked by spinning down 250 uL of
cells suspension at 4400 rpm for 5mim. The pellet was re-suspended in 100 uL lysis buffer, then
20 uL of lysate was mixed with 20 uL of sodium dodecyl sulfate (SDS) loading buffer and
heated at 95˚C for 5 minutes. The sample was centrifuged and supernatant was loaded into SDSPAGE to check the expression level.
Minimal medium was composed of M9 salts (64 g Na2HPO4, 15 g KH2PO4, 2.5 g NaCl,
and 5 g NH4Cl into 1000 mL of MiliQ water), 1M MgSO4, 20% glucose, 1M CaCl2. The MgSO4,
glucose, and CaCl2 were sterilized with a 0.2 um Milipore Stericup vacuum filtration system. To
prepare the minimal media, 200 ml of M9 salts were added to 700 ml of sterile MilliQ, then 2 ml
of 1 M MgSO4, 20 ml of 20% glucose, 100 ul of 1 M CaCl2 were added last then the volume was
adjusted to 1000 ml with sterile miliQ water. Minimal medial was only used if expression levels
appeared to be low, otherwise cultures were grown in LB.
4.3.2.3 Large scale expression
One colony selected from the plate with the highest expression levels was inoculated into
100mL of LB media with amp(100 uM)/kan(50 uM) antibiotics and grown overnight at 37˚C,
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then the cells were gently spun down at 4400 rpm for 15 minutes at room temperature and the
pellet was re-suspended in 500 mL of minimal medium (2:10 ratio of bacteria culture to flask
volume) and incubated at 37˚C. Once O.D.600 reached 0.6-0.7 the culture was induced for 4 hours
(1 mM IPTG).
4.3.2.4 Cell Lysis and Protein purification
After induction the cells were collected by centrifuging at 5000 rpm for 15 minutes at
4˚C using a Sorvall Centrifuge RC28S (Wilmington, DE, USA) with GSA rotor, and lysed in
100 mM NaH2PO4, 10 mM Tris-HCl, 10 mM imidazole, and 8 M urea (pH 8), under agitation,
for 30 minutes at 4°C. The cell lysate formed was further disrupted by sonication at 60 W for 3 x
30 s pulses (with 1min delay between pulses) on ice bath, with a Branson Sonifer 450. The
soluble material was recovered by centrifugation at 11000 rpm for 20 minutes using a Sorvall
Centrifuge RC28S with F28⁄36 rotor.
Recombinant mutants and wild type PCZN proteins were purified using affinity
chromatography. The solubilized His-tagged recombinant proteins were mixed with preequilibrated Ni-nitrilotriacetic acid (NTA)-agarose resin (loaded with Ni2+) (ThermoFisher) for
15 min. Unbound protein was allowed to pass through the column and the column was washed
with wash buffer (100 mM NaH2PO4, 10 mM Tris-HCl, and 8 M urea pH 6.3). The recombinant
proteins were then eluted with elution buffer using gradient concentrations of imidazole (10, 30,
50, and 200 mM). Then the purity of recombinant proteins was checked by 12% SDS-PAGE.
The eluted samples were pooled and submitted to in vitro refolding by incubation with 5 mM
dithiothreitol at 37 °C for 45 minutes, followed by 20-fold dilution in ice-cold 100 mM Tris-HCl
(pH 8), 1 mM EDTA, 1 M KCl, and 20% glycerol, and further incubation at 4 °C for 24 h. The
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solution was concentrated in a mini-reservoir (RC800 Millipore)) under nitrogen pressure to a
final volume of 30 mL using 0.2 um cellulose acetate filters (Millipore, Bedford, MA, USA) at
4°C. Protein concentration was measured with Nano Drop 1000 instrument (Thermo Scientific,
software ND 100 v3.6.0) by using extinction coefficient of 63,500 cm-1M-1and molecular weight
of 35.4 kDa.
4.3.2.5 Protein Refolding
Aliquots with pure PCZN protein were combined and a final concentration of 30 uM
dithiothreitol (DTTred) was added to the pooled fractions and incubated at 37˚C under slight
agitation for 1 hour. The resulted denatured and reduced protein was diluted 20 times in
refolding buffer (250 mM Arginine, 100 mM Tris HCl, 1 mM EDTA and 20% Glycerol, pH 8.0)
and incubated under slight agitation at 4˚C overnight as previously described21. The sample was
dialyzed using a 3 kDa MWCO Ultracel membrane filter (Millipore) prior to being concentrated
to a final volume of 20 mL. Refolded protein was used for kinetic studies obtained by
fluorescence spectroscopy.
4.3.3 Kinetic Study of Mutants in comparison with wild type procruzain
All recombinant proteins were purified, refolded and dialyzed as mentioned in chapter 2.
After protein was refolded and dialyzed with cold water, the protein concentration was adjusted
to 0.3 mg/mL. Protease activity of recombinant mutants and WT pczp was measured using ZPhe-Arg-7-amido-4-methyl-coumarin-HCl (AMC) as substrate (where Z is benzyloxycarbonyl),
and performed as previously described75 with modifications. Activation assays were performed
in a DM45 Spectrofluorimeter (On-line Instrument Systems, Inc.) using Spectra Works software
and were carry out in a quartz cuvette 1cm path length (Fisher Scientific). Fluorescence was
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recorded as a function of time at 440 nm emission wavelength and 380 nm excitation wavelength
and set for 0.100 integration time and 600 PMT HV. The reaction cuvette, with a total volume of
2050 uL, was filled with activation buffer (5 mM EDTA, 100 mM NaH2PO4, 200 mM NaCl, 2
mM DTTred, pH 4.5) and substrate (40 uM AMC), 5 mM EDTA, 50 mM NaH2PO4, 100 mM
NaCl, 5 mM DTTred) and adjusted to pH 5.3. Reaction was then initiated by addition of 50 uL
of refolded protein at a concentration of 0.3 mg/mL. The fluorescence was recorded promptly
after protein addition and incubated at 37˚C for a period of 5000 seconds. When maximum
activity was observed, the mature enzyme was inhibited with 10 uM Leupeptin (Sigma) for 15
min at 37 ˚C. An aliquot of the active protein was lyophilized and run on 12% SDS-PAGE and
gels were stained in Coomassie brilliant blue R-250 (BioRad).
Refolded protein was dialyzed against Phosphate-buffered saline buffer (PBS) pH 7.4
using 3 kDa MWCO tubes (GE Healthcare) and further concentrated using centrifugal filter
tubes (Vivaspin2, 3 kDa MWCO). Resultant dialyzed protein was passed through PVDF 0.22 um
filters (Fisherbrand) to remove any debris of precipitated protein. Protein concentration was
measured using NanoDrop instrument (Thermo Scientific Nano Drop 1000, software ND 100
v3.6.0). Assays were performed in 0.1 cm path length quartz cuvette (Fisher Scientific). After
protein folding and determination of concentration the extent of protein folding, and activity
were analyzed with fluorescence spectroscopy.
Protease activity of recombinant mutants and PCZN-WT was measured using Z-Phe-Arg-7amido-4-methyl-coumarin-HCl (AMC) as substrate, and performed as previously described16
with modifications. Activation assays were performed in a DM45 Spectrofluorometer (On-line
Instrument Systems, Inc.) using Spectra Works software and were carried out in a quartz cuvette
1cm path length (Fisher Scientific). Fluorescence was recorded as a function of time at 440 nm
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emission wavelength and 380 nm excitation wavelength and set for 0.100 integration time and
600 PMT HV. Recombinant protein was added to a 1:1 activation buffer (200 mM NaCH3COO,
1.8 M NaCl, 10 mM DTTred and 10 mM EDTA, pH 5.2) to substrate buffer (40 uM Z-F-R-AMC,
5 mM EDTA, 50 mM NaH2PO4, 100 mM NaCl, 5 mM DTTred) for a final protein concentration
of 7.32 ug/mL and pH of 5.3. The fluorescence was recorded promptly after protein addition and
incubated at 37℃ for a period of 50,000 seconds. When maximum activity was observed, the
mature enzyme was inhibited with 10 uM Leupeptin (Sigma) for 15 minutes at 37 ℃ to prevent
auto-degradation of the protein. An aliquot of the active protein was lyophilized and run on 12%
SDS-PAGE and gels were stained in Coomassie brilliant blue R-250 (BioRad).

4.4 Results and discussion
4.4.1 Molecular dynamics results
Amino acid residues that are highly conserved among parasitic cysteine proteases but not human
are targeted in our studies. The following results were provided by sequencing alignment.
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Figure 46: Result of sequence alignment studies
The molecular modeling studies identified the following mutations as potential structure stabilizing targets.
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Table 8: List of Targets and their Mutations

Target Number

Mutation (including histag)

1

D70V (D82V)

2

E75V (E87V)

3

F20A (F32A)

4

F23A (F35A)

5

F44A (F56A)

6

E13V (E25V)

7

E37V (E49V)

8

E74V (E86V)

Negative Control

C129A (C141A)

4.4.2 Expression results
All eight targets were expressed and purified. They were run on a12% SDS-PAGE
determine expression level and purity. The diagrams below are photos of the gels after the
purification of each target. The purest fractions were pooled, the concentration of each protein
was determined and prepared for fluorescence analysis of protein folding and activity.
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Figure 47: Expression Results of Selected Targets
Figure 47 A and B =C129A, C=Target 1 (D70V), D=Wild-type, E=Target 2 (E75V), and F=Target 6 (E13V)
were expressed for protein folding studies. The remaining targets 4 (F23A), 5 (F44A), 7 (E37V), and 8
(E74V) were expressed at a later time.
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Figure 48: Expression results of Targets 4, 5, 7 and 8
The remaining targets were expressed and also analyzed with fluorescence spectroscopy. A =
Target 4, B =Target 5, C= Target 7, D=Target 8. A low yield of Target 3 was obtained (not
shown).

It is now fully known why expression levels were different for each target. In fact, with in
the same target, the quantities of purified product differed between expression. One issue could
have occurred with the plasmid construction. The purest fractions of the expression were collected,
refolded and used for fluorescence spectroscopy studies.
4.4.3 Activation assays of recombinant mutants and wild type procruzain
Although pro domains of several cysteine proteases have shown to be potent inhibitors of
other papain-like enzymes69, no studies have been done on identification of critical residues of
these pro domains with the final objective of protein early inactivation. In our study, enzymatic
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activity of recombinant cysteine proteases was accessed by the liberation of the fluorescent leaving
group 7-amino-4-methyl-coumarin (AMC) from the peptide substrate Z-Phe-Arg-AMC and the
fluorogenic molecule was measured (Figure X). Slope of the curve of the autoactivation of PCZN
and its mutants resulted as follows: WT= 8.43x10-4, E25V= 2.56x10-4, E87V= 3.73x10-4, D82V=
1.31x10-5. From the observed results, D82V mutation was found to be the most deleterious
compared to WT, followed by E25V and lastly E87V. As it has been stablished that mutation of
active site of subtilisin (S22C) does not affect the folding rate70, we considered mutant C25A
(C141A) as negative control for the studies for autoactivation of mutants. Therefore, C141A
mutant showed no activity as expected. The low rate of autoactivation of mutant D82V may be as
a consequence of a change in the backbone conformation of Glu44 and Val82 that destabilized the
protein even more so than the rest of the mutants.
Although mutant E25V was proposed as important residue by sequence alignment studies
and by folding characterization, it showed a decrement in autoactivation rate during the abovementioned experimental analysis. Although neither of the mutants are not completely inactive,
residue mutations have reduced the proteinase activity by delaying the reach of the substrate.
Previous studies have shown the effect of mutated pro domains of proteases. That is the case of
subtilisin E, where mutations generated within the pro-peptide were incapable of producing an
active subtilisin,75 or in the case of cathepsin L that resulted in improper folding after deletions in
its pro domain.70 Nevertheless, not all mutations produced a negative effect on the activity of
proteases as demonstrated in another study done by Ruan et al., 199976 where mutated pro-peptide
increases subtilisin’s folding rate when compared to WT pro-peptide. Indeed, our mutants caused
a deleterious effect on the rate of PCZN’s autoactivation proving important information for the
identification for structural destabilization sites within the pro domain.
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Pro-domain mutations can indeed have critical effect on enzyme activity. The almost
complete lack of activity in D82V mutant signifies that it could act as a potential therapeutic target.
Other mutations, had increased autoactivation time, but, once they got activated, they reached
similar Vmax compared to the PCZN-WT. D82V activation mimicked the C141A active site mutant
which had hardly any activity. What effect does D82V mutation has on the enzyme leading to
complete lack of activity needs further in-depth study.

Figure 49: Activation of recombinant PCZN-WT and mutants.
The kinetics of autoactivation of recombinant PCZN was monitored from cleavage of AMC from Z-Phe-ArgAMC substrate. Diamonds: PCZN-WT, cross marks: E25V, squares: PCZN-D82V, triangles: PCZN-D87V,
circles: PCZ-C141A, stars: activation buffer alone.
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Previous studies have shown the effect of mutated pro domains of proteases. That is the
case of subtilisin E, where mutations G2R, M20T, K35E, and V67A generated within the propeptide were incapable of producing an active subtilisin; or in the case of cathepsin L that resulted
in improper folding after deletions in its pro domain.74,75 Nevertheless, no all mutations produced
a negative effect on the activity of proteases where in another study done by Ruan et al., 199976 ,
mutated pro-peptide increases subtilisin’s folding rate when compared to WT pro-peptide. Indeed,
our mutants caused a negative effect on the rate of PCZN’s autoactivation proving important
information for the identification for structural destabilization sites within the pro domain.
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CHAPTER 5
CONCLUSION
To date we have been able to refine the methods of expression, purification and activation
of cruzain. It is believed that the prodomain can help the folding of the protein in vivo however
no data has been given on the effect of the folding rate. Our initial folding data suggests that the
prodomain is not necessary for folding and may the slow regeneration process however several
amino acid residues within the prodomain are imperative to the structure and essential the function
of the cruzain. Mutations of structure stabilizing amino acid residues provided in this work
resulted in a decrease in enzymatic activity for all the targets but one. Target 5 (F44A) showed an
increase in activity possibly due to the increased interaction of arginine or phenylamine residues
with the active site, promoting autodegradation. Future studies can be done on combining
mutations to further impede protein folding and activity. Thereafter, small molecules can be
synthesized to target those structure stabilizing reactions to prevent protein folding, enzymatic
activity and the progression of the Chagas disease.
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FUTURE PLANS
As future plans, additional mutations, possibly not limited to the prodomain, can be carried
out to determine the role of the reside in protein folding. In the future, small molecules cans be
developed to target these resides to prevent folding and maturation of procruzain to cruzain.
Point mutations that showed to slow protein folding in our studied can be combined to analyze the
additive effect of both mutations. In addition, mutagenesis of observed hydrophobic cluster within
the pro domain, compromised of phenylalanine 32, 35 and 56, may be valuable to determine its
implication in protein destabilization.

Insight to amino acid residue interactions that

destabilization of these interactions can give us great insight in producing anti-chagastics drugs.
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